Acetylsalicylic acid$Drug$DB00945$ACETAZOLAMIDE$Drug$DB00819$true$Increase_Interaction$
Acetylsalicylic acid$Drug$DB00945$Apixaban$Drug$DB06605$true$Specific_Interaction$
Acetylsalicylic acid$Drug$DB00945$Clopidogrel$Drug$DB00758$true$Specific_Interaction$
Acetylsalicylic acid$Drug$DB00945$Nitroglycerin$Drug$DB00727$true$Increase_Interaction$
Adenosine$Drug$DB00640$CARBAMAZEPINE$Drug$DB00564$true$Specific_Interaction$
Adenosine$Drug$DB00640$Digoxin$Drug$DB00390$true$Caution_Interaction$Drug Label for drug brand Adenocard, containing adenosine.; 
Adenosine$Drug$DB00640$Dipyridamole$Drug$DB00975$true$Increase_Interaction$
Aliskiren$Drug$DB01258$Amlodipine$Drug$DB00381$true$Caution_Interaction$&lt;item&gt;Lotrel is contraindicated in patients with a history of angioedema, with or without previous ACE inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ACE inhibitor, to amlodipine, or to any of the excipients of Lotrel.; Antidiabetic agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. ; Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. ; Monitor renal function periodically in patients receiving benazepril and NSAID therapy.; Closely monitor blood pressure, renal function and electrolytes in patients on Lotrel and other agents that block the RAS.; Do not co-administer aliskiren with Lotrel in patients with diabetes. ; Avoid use of aliskiren with Lotrel in patients with renal impairment (GFR 60 ml/min).; The antihypertensive effect of ACE inhibitors, including benazepril, may be attenuated by NSAIDs.; Such patients should therefore be advised about the possibility of hypoglycemic reactions, and should be monitored accordingly.; 
Aliskiren$Drug$DB01258$Azilsartan medoxomil$Drug$DB08822$true$Caution_Interaction$
Aliskiren$Drug$DB01258$Benazepril$Drug$DB00542$true$Caution_Interaction$Avoid use of aliskiren with Lotensin in patients with renal impairment (GFR &lt;60 ml/min).; Closely monitor blood pressure, renal function and electrolytes in patients on Lotensin and other agents that affect the RAS.; Do not co-administer aliskiren with Lotensin in patients with diabetes. ; Other: Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions. ; The antihypertensive effect of ACE inhibitors, including benazepril, may be attenuated by NSAIDs.; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including benazepril, may result in deterioration of renal function, including possible acute renal failure. ; Dual Blockade of the Renin-Angiotensin System (RAS): Dual Blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypertension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. ; Monitor renal function periodically in patients receiving benazepril and NSAID therapy.; 
Aliskiren$Drug$DB01258$Candesartan$Drug$DB00796$true$Caution_Interaction$Drug Label for drug brand ATACAND, containing Candesartan cilexetil.; 
Aliskiren$Drug$DB01258$CYCLOSPORINE$Drug$DB00091$true$Caution_Interaction$Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or non-steroidal anti-inflammatory (NSAID) therapy may be at particular risk for developing acute renal failure on Tekamlo see Contraindications (4), Warnings and Precautions (5.2), Clinical Studies (14.2). ; Avoid concomitant use of aliskiren with cyclosporine or intraconazole see Drug Interactions (7).; Monitor serum potassium periodically in patients receiving aliskiren. ; Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function.; When aliskiren was given with cyclosporine or itraconazole, the blood concentrations of aliskiren were significantly increased. ; 
Aliskiren$Drug$DB01258$Enalapril$Drug$DB00584$true$Caution_Interaction$Do not coadminister aliskiren with VASOTEC in patients with diabetes. ; Dual Blockade of the Renin-Angiotensin System (RAS); Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. ; Avoid use of aliskiren with VASOTEC in patients with renal impairment (GFR &lt;60 mL/min).; Closely monitor blood pressure, renal function, and electrolytes in patients on VASOTEC and other agents that affect the RAS.; 
Aliskiren$Drug$DB01258$Eprosartan$Drug$DB00876$true$Caution_Interaction$Do not co-administer aliskiren with TEVETEN in patients with diabetes (see PRECAUTIONS, Drug Interactions).; 
Aliskiren$Drug$DB01258$Irbesartan$Drug$DB01029$true$Caution_Interaction$Drug Label for drug brand Avapro, containing irbesartan.; 
Aliskiren$Drug$DB01258$Lisinopril$Drug$DB00722$true$Caution_Interaction$Avoid use of aliskiren with PRINIVIL in patients with renal impairment (GFR &lt;60ml/min).; Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including PRINIVIL. ; This interaction should be given consideration in patients taking NSAIDs or selective COX-2 inhibitors concomitantly with ACE inhibitors.; Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. ; Closely monitor blood pressure, renal function and electrolytes in patients on ZESTRIL and other agents that affect the RAS.; Do not co-administer aliskiren with ZESTRIL in patients with diabetes. ; Do not coadminister aliskiren with PRINIVIL in patients with diabetes. ; No clinically important pharmacokinetic interactions occurred when ZESTRIL was used concomitantly with propranolol or hydrochlorothiazide. ; Avoid use of aliskiren with ZESTRIL in patients with renal impairment (GFR &lt; 60 ml/min).; Dual Blockade of the Renin-Angiotensin System (RAS); Dual Blockade of the Renin-angiotensin-aldosterone System: Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with angiotensin receptor blockers, ACE inhibitors, or direct renin inhibitors (such as aliskiren) is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. ; In some patients with compromised renal function (e.g., elderly patients or patients who are volume-depleted including those on diuretic therapy) who are being treated with non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors, the co-administration of angiotensin II receptor antagonists or ACE inhibitors may result in a further deterioration of renal function, including possible acute renal failure. ; Other Agents: ZESTRIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions. ; These interactions should be considered in patients taking NSAIDS including selective COX-2 inhibitors concomitantly with diuretics and angiotensin II antagonists or ACE inhibitors. ; Agents Increasing Serum Potassium: ZESTRIL attenuates potassium loss caused by thiazide-type diuretics. ; Closely monitor blood pressure, renal function, and electrolytes in patients on PRINIVIL and other agents that affect the RAAS. ; In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.; 
Aliskiren$Drug$DB01258$Losartan$Drug$DB00678$true$Caution_Interaction$Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors); Avoid use of aliskiren with losartan potassium and hydrochlorothiazide in patients with renal impairment (GFR &lt;60 ml/min).; Closely monitor blood pressure, renal function, and electrolytes in patients on losartan potassium and hydrochlorothiazide and other agents that affect the RAS.; The antihypertensive effect of angiotensin II receptor antagonists, including losartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors.; Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. ; Dual Blockade of the Renin-Angiotensin System (RAS); Monitor renal function periodically in patients receiving losartan and NSAID therapy.; Do not co-administer aliskiren with losartan potassium and hydrochlorothiazide in patients with diabetes. ; In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including losartan) may result in deterioration of renal function, including possible acute renal failure. ; 
Aliskiren$Drug$DB01258$Olmesartan$Drug$DB00275$true$Caution_Interaction$
Aliskiren$Drug$DB01258$Perindopril$Drug$DB00790$true$Caution_Interaction$7.8 Dual Blockade of the Renin-Angiotensin System (RAS); Avoid use of aliskiren with ACEON in patients with renal impairment (GFR 60 ml/min).; In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including perindopril, may result in deterioration of renal function, including possible acute renal failure. ; Closely monitor blood pressure, renal function and electrolytes in patients on ACEON and other agents that affect the RAS.; Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. ; ACEON (perindopril erbumine) is contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor. ; Monitor renal function periodically in patients receiving perindopril and NSAID therapy.; The antihypertensive effect of ACE inhibitors, including perindopril, may be attenuated by NSAIDs including selective COX-2 inhibitors.; Do not co-administer aliskiren with ACEON in patients with diabetes. ; Drug Label for drug brand Aceon, containing perindopril erbumine.; 
Aliskiren$Drug$DB01258$Quinapril$Drug$DB00881$true$Caution_Interaction$
Aliskiren$Drug$DB01258$Telmisartan$Drug$DB00966$true$Caution_Interaction$Drug Label for drug brand Micardis, containing telmisartan.; 
Aliskiren$Drug$DB01258$Trandolapril$Drug$DB00519$true$Caution_Interaction$Dual Blockade of the Renin-Angiotensin System (RAS); Closely monitor blood pressure, renal function and electrolytes in patients on MAVIK and other agents that affect the RAS.; Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. ; Do not co-administer aliskiren with MAVIK in patients with diabetes. ; As with other ACE inhibitors, patients on diuretics, especially those on recently instituted diuretic therapy, may experience an excessive reduction of blood pressure after initiation of therapy with MAVIK. ; Avoid use of aliskiren with MAVIK in patients with renal impairment (GFR &lt;60 ml/min).; If it is not possible to discontinue the diuretic, the starting dose of trandolapril should be reduced. ; Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. ; The possibility of exacerbation of hypotensive effects with MAVIK may be minimized by either discontinuing the diuretic or cautiously increasing salt intake prior to initiation of treatment with MAVIK. ; 
Aliskiren$Drug$DB01258$Valsartan$Drug$DB00177$true$Caution_Interaction$Do not coadminister aliskiren with Diovan in patients with diabetes [See Drug Interactions (7)].; 
Alprazolam$Drug$DB00404$Digoxin$Drug$DB00390$true$Increase_Interaction$
Alteplase$Drug$DB00009$Nitroglycerin$Drug$DB00727$true$Decrease_Interaction$
Aluminium$Drug$DB01370$Polystyrene sulfonate$Drug$DB01344$true$Specific_Interaction$
AMIODARONE$Drug$DB01118$Digoxin$Drug$DB00390$true$Increase_Interaction$If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity.; There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone. ; Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. ; Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity. ; Phenytoin decreases serum amiodarone levels. ; Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days. ; Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone. ; NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment.; On administration of oral amiodarone, review the need for digitalis therapy and reduce the dose of digitalis by approximately 50% or discontinue digitalis. ; Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. ; 
AMIODARONE$Drug$DB01118$LOVASTATIN$Drug$DB00227$true$Caution_Interaction$If lovastatin is co-administered with amiodarone, do not exceed doses greater than 40 mg daily of lovastatin.; There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.; &lt;item&gt;Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation. ; If simvastatin is co-administered with amiodarone, do not exceed doses greater than 20 mg daily of simvastatin. ; This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes or are substrates for p-glycoprotein. ; 
AMIODARONE$Drug$DB01118$PROCAINAMIDE$Drug$DB01035$true$Increase_Interaction$Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. ; If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity.; Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity. ; Phenytoin decreases serum amiodarone levels. ; Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days. ; On administration of oral amiodarone, review the need for digitalis therapy and reduce the dose of digitalis by approximately 50% or discontinue digitalis. ; Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone. ; Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. ; NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment.; There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone. ; 
AMIODARONE$Drug$DB01118$QUINIDINE$Drug$DB00908$true$Increase_Interaction$Phenytoin decreases serum amiodarone levels. ; Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone. ; Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. ; On administration of oral amiodarone, review the need for digitalis therapy and reduce the dose of digitalis by approximately 50% or discontinue digitalis. ; Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. ; Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days. ; If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity.; NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment.; Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity. ; There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone. ; 
AMIODARONE$Drug$DB01118$Simvastatin$Drug$DB00641$true$Caution_Interaction$There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.; If simvastatin is co-administered with amiodarone, do not exceed doses greater than 20 mg daily of simvastatin. ; This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes or are substrates for p-glycoprotein. ; If lovastatin is co-administered with amiodarone, do not exceed doses greater than 40 mg daily of lovastatin.; &lt;item&gt;Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation. ; 
Amitriptyline$Drug$DB00321$Clonidine$Drug$DB00575$true$Specific_Interaction$CATAPRES-TTS transdermal therapeutic system should not be used in patients with known hypersensitivity to clonidine or to any other component of the therapeutic system.; Catapres (clonidine hydrochloride, USP) tablets should not be used in patients with known hypersensitivity to clonidine (see PRECAUTIONS ).; 
Amlodipine$Drug$DB00381$LITHIUM$Drug$DB01356$true$Caution_Interaction$&lt;item&gt;Do not co-administer aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotrel in patients with diabetes.; 
ATORVASTATIN$Drug$DB01076$COLCHICINE$Drug$DB01394$true$Specific_Interaction$
ATORVASTATIN$Drug$DB01076$CYCLOSPORINE$Drug$DB00091$true$Specific_Interaction$Select doses of amlodipine and atorvastatin independently.; 
BOSENTAN$Drug$DB00559$ETHINYL ESTRADIOL$Drug$DB00977$true$Decrease_Interaction$An interaction study demonstrated that coadministration of bosentan and a combination oral hormonal contraceptive produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively. ; Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A. ; The concomitant administration of Tracleer and cyclosporine A is contraindicated see Contraindications (4.2).; Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when Tracleer is coadministered. ; During the first day of concomitant administration, trough concentrations of bosentan were increased by about 30-fold. ; Females should practice additional methods of contraception and not rely on hormonal contraception alone when taking Tracleer see Boxed Warning, Contraindications (4.1).; However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects.; The mechanism of this interaction is most likely inhibition of transport protein-mediated uptake of bosentan into hepatocytes by cyclosporine. ; 
Bosentan$Drug$DB00559$GLYBURIDE$Drug$DB01016$true$Caution_Interaction$The plasma concentrations of bosentan were also decreased by approximately 30%. ; The possibility of worsened glucose control in patients using these agents should be considered.; Coadministration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A substrate) by approximately 50%.; 7.5 Lopinavir/Ritonavir or Other Ritonavir-containing HIV Regimens; An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide. ; Therefore, the concomitant administration of Tracleer and glyburide is contraindicated, and alternative hypoglycemic agents should be considered see Contraindications (4.3).; Coadministration of bosentan decreased the plasma concentrations of glyburide by approximately 40%. ; Tracleer is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A. ; An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide. ; 7.5 Lopinavir/Ritonavir or Other Ritonavir-containing HIV Regimens; Coadministration of bosentan decreased the plasma concentrations of glyburide by approximately 40%. ; Therefore, the concomitant administration of Tracleer and glyburide is contraindicated, and alternative hypoglycemic agents should be considered see Contraindications (4.3).; Tracleer is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A. ; The possibility of worsened glucose control in patients using these agents should be considered.; Coadministration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A substrate) by approximately 50%.; The plasma concentrations of bosentan were also decreased by approximately 30%. ; 
BOSENTAN$Drug$DB00559$GLYBURIDE$Drug$DB01016$true$Decrease_Interaction$The plasma concentrations of bosentan were also decreased by approximately 30%. ; The possibility of worsened glucose control in patients using these agents should be considered.; Coadministration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A substrate) by approximately 50%.; 7.5 Lopinavir/Ritonavir or Other Ritonavir-containing HIV Regimens; An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide. ; Therefore, the concomitant administration of Tracleer and glyburide is contraindicated, and alternative hypoglycemic agents should be considered see Contraindications (4.3).; Coadministration of bosentan decreased the plasma concentrations of glyburide by approximately 40%. ; Tracleer is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A. ; An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide. ; 7.5 Lopinavir/Ritonavir or Other Ritonavir-containing HIV Regimens; Coadministration of bosentan decreased the plasma concentrations of glyburide by approximately 40%. ; Therefore, the concomitant administration of Tracleer and glyburide is contraindicated, and alternative hypoglycemic agents should be considered see Contraindications (4.3).; Tracleer is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A. ; The possibility of worsened glucose control in patients using these agents should be considered.; Coadministration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A substrate) by approximately 50%.; The plasma concentrations of bosentan were also decreased by approximately 30%. ; 
BOSENTAN$Drug$DB00559$NORETHINDRONE$Drug$DB00717$true$Decrease_Interaction$An interaction study demonstrated that coadministration of bosentan and a combination oral hormonal contraceptive produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively. ; The concomitant administration of Tracleer and cyclosporine A is contraindicated see Contraindications (4.2).; During the first day of concomitant administration, trough concentrations of bosentan were increased by about 30-fold. ; Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when Tracleer is coadministered. ; Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A. ; Females should practice additional methods of contraception and not rely on hormonal contraception alone when taking Tracleer see Boxed Warning, Contraindications (4.1).; However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects.; The mechanism of this interaction is most likely inhibition of transport protein-mediated uptake of bosentan into hepatocytes by cyclosporine. ; 
BOSENTAN$Drug$DB00559$Sildenafil$Drug$DB00203$true$Decrease_Interaction$In normal volunteers, coadministration of multiple doses of 125 mg twice daily bosentan and 80 mg three times daily sildenafil resulted in a reduction of sildenafil plasma concentrations by 63% and increased bosentan plasma concentrations by 50%. ; Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.; Clinical experience with concomitant administration of Tracleer and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among Tracleer- and placebo-treated patients.; Coadministration of bosentan 500 mg twice daily for 6 days in normal volunteers decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A substrate) by 29 and 38%, respectively. ; Coadministration of bosentan 125 mg twice daily and ketoconazole, a potent CYP3A inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold in normal volunteers. ; 7.11 Digoxin, Nimodipine, and Losartan; No dose adjustment of Tracleer is necessary, but increased effects of Tracleer should be considered.; 
Buspirone$Drug$DB00490$DILTIAZEM$Drug$DB00343$true$Increase_Interaction$
Carbamazepine$Drug$DB00564$Hydrochlorothiazide$Drug$DB00999$true$Specific_Interaction$Carbamazepine: concomitant use of carbamazepine and hydrochlorothiazide has been associated with the risk of symptomatic hyponatremia. ; Electrolytes should be monitored during concomitant use.; 
Carvedilol$Drug$DB01136$DILTIAZEM$Drug$DB00343$true$Specific_Interaction$As with other agents with  -blocking properties, if COREG is to be administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.; Rifampin reduced plasma concentrations of carvedilol by about 70% [see Clinical Pharmacology (12.5)]. ; The concomitant administration of amiodarone or other CYP2C9 inhibitors such as fluconazole with COREG may enhance the  -blocking properties of carvedilol resulting in further slowing of the heart rate or cardiac conduction. ; 7.8 Insulin or Oral Hypoglycemics; Amiodarone, and its metabolite desethyl amiodarone, inhibitors of CYP2C9 and P-glycoprotein, increased concentrations of the S(-)-enantiomer of carvedilol by at least 2-fold [see Clinical Pharmacology (12.5)]. ; Conduction disturbance (rarely with hemodynamic compromise) has been observed when COREG is co-administered with diltiazem. ; Patients should be observed for signs of bradycardia or heart block, particularly when one agent is added to pre-existing treatment with the other.; Cimetidine increased AUC by about 30% but caused no change in Cmax[see Clinical Pharmacology (12.5)].; 
Cilostazol$Drug$DB01166$CLOPIDOGREL$Drug$DB00758$true$Caution_Interaction$PLETAL (cilostazol) tablet; 
Cilostazol$Drug$DB01166$DILTIAZEM$Drug$DB00343$true$Increase_Interaction$PLETAL (cilostazol) tablet; 
Cimetidine$Drug$DB00501$AMIODARONE$Drug$DB01118$true$Increase_Interaction$Cimetidine inhibits CYP3A and can increase serum amiodarone levels.; QT interval prolongation and TdP have been reported with the co-administration of trazodone and amiodarone.; Do not take grapefruit juice during treatment with amiodarone.; QT interval prolongation and TdP have been reported with the co-administration of loratadine and amiodarone.; Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone. ; Trazodone, an antidepressant, is metabolized primarily by CYP3A. ; 
Cimetidine$Drug$DB00501$Dofetilide$Drug$DB00204$true$Caution_Interaction$TIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. ; 
Cimetidine$Drug$DB00501$Dofetilide$Drug$DB00204$true$Increase_Interaction$TIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. ; 
Cimetidine$Drug$DB00501$Dofetilide$Drug$DB00204$true$Specific_Interaction$TIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. ; 
Cimetidine$Drug$DB00501$Felodipine$Drug$DB01023$true$Increase_Interaction$
Cimetidine$Drug$DB00501$LIDOCAINE PATCH$Drug$DB05291$true$Increase_Interaction$Xylocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. ; 
Cimetidine$Drug$DB00501$LIDOCAINE PATCH$Drug$DB05291$true$Specific_Interaction$Xylocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. ; 
Cimetidine$Drug$DB00501$Losartan$Drug$DB00678$true$Increase_Interaction$Drug Label for drug brand Losartan Potassium, containing losartan potassium.; Drug Label for drug brand losartan potassium and hydrochlorothiazide, containing losartan potassium and hydrochlorothiazide.; 
Cimetidine$Drug$DB00501$Nicardipine$Drug$DB00622$true$Increase_Interaction$CARDENE SR capsules for oral administration each contain 30 mg, 45 mg or 60 mg of nicardipine hydrochloride.; 
CISPLATIN$Drug$DB00515$Furosemide$Drug$DB00695$true$Specific_Interaction$LASIX tablets for oral administration contain furosemide as the active ingredient and the following inactive ingredients: lactose monohydrate NF, magnesium stearate NF, starch NF, talc USP, and colloidal silicon dioxide NF. ; 
CLARITHROMYCIN$Drug$DB01211$ATORVASTATIN$Drug$DB01076$true$Caution_Interaction$
CLARITHROMYCIN$Drug$DB01211$Digoxin$Drug$DB00390$true$Increase_Interaction$
CLARITHROMYCIN$Drug$DB01211$RIVAROXABAN$Drug$DB06228$true$Increase_Interaction$In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; 
CLARITHROMYCIN$Drug$DB01211$RIVAROXABAN$Drug$DB06228$true$Specific_Interaction$In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; 
Clonidine$Drug$DB00575$DILTIAZEM$Drug$DB00343$true$Specific_Interaction$Catapres (clonidine hydrochloride, USP) tablets should not be used in patients with known hypersensitivity to clonidine (see PRECAUTIONS ).; NEXICLON XR should not be used in patients with known hypersensitivity to clonidine see Warnings and Precautions (5.2); 
Clonidine$Drug$DB00575$ETHANOL$Substance$DB00898$true$Specific_Interaction$CATAPRES-TTS (clonidine) is a transdermal system providing continuous systemic delivery of clonidine for 7 days at an approximately constant rate.; Catapres (clonidine hydrochloride, USP) tablets should not be used in patients with known hypersensitivity to clonidine (see PRECAUTIONS ).; NEXICLON XR should not be used in patients with known hypersensitivity to clonidine see Warnings and Precautions (5.2); 
Clonidine$Drug$DB00575$Verapamil$Drug$DB00661$true$Specific_Interaction$Biochemical evidence points to separate binding sites for 1,4-dihydropyridines, phenylalkylamines, and the benzothiazepines (all located on the alpha-1 subunit). ; Catapres (clonidine hydrochloride, USP) tablets should not be used in patients with known hypersensitivity to clonidine (see PRECAUTIONS ).; It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.; Monitor heart rate in patients receiving concomitant verapamil and clonidine.; NEXICLON XR should not be used in patients with known hypersensitivity to clonidine see Warnings and Precautions (5.2); Hypotension and bradyarrhythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.; Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). ; The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. ; Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. ; Hypotension and bradyarrhythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class.; Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.; Verapamil can increase doxorubicin levels. ; Verapamil should be avoided in patients with severe left ventricular dysfunction (eg, ejection fraction less than 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker (see PRECAUTIONS, Drug interactions). ; 
CLOPIDOGREL$Drug$DB00758$AMIODARONE$Drug$DB01118$true$Specific_Interaction$Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, reduce the dose of the anticoagulant by one-third to one-half, and monitor prothrombin times closely.; Clopidogrel, an inactive thienopyridine prodrug, is metabolized in the liver by CYP3A to an active metabolite. ; A potential interaction between clopidogrel and amiodarone resulting in ineffective inhibition of platelet aggregation has been reported.; Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A (enzyme induction). ; This may lead to low amiodarone serum levels and potential decrease in efficacy. ; Potentiation of warfarin -type (CYP2C9 and CYP3A substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding. ; 
CLOPIDOGREL$Drug$DB00758$Dabigatran etexilate$Drug$DB06695$true$Increase_Interaction$
Clopidogrel$Drug$DB00758$ESOMEPRAZOLE$Drug$DB00736$true$Caution_Interaction$
Clopidogrel$Drug$DB00758$ESOMEPRAZOLE$Drug$DB00736$true$Specific_Interaction$
CLOPIDOGREL$Drug$DB00758$Rivaroxaban$Drug$DB06228$true$Specific_Interaction$Coadministration of the platelet aggregation inhibitor clopidogrel and XARELTO resulted in an increase in bleeding time for some subjects [see Clinical Pharmacology (12.3)].; XARELTO should be used in patients with CrCl 15 to 50 mL/min who are receiving concomitant combined P-gp and weak or moderate CYP3A4 inhibitors only if the potential benefit justifies the potential risk [see Clinical Pharmacology (12.3)].; Patients with renal impairment receiving full dose XARELTO in combination with drugs classified as combined P-gp and weak or moderate CYP3A4 inhibitors (e.g., amiodarone, diltiazem, verapamil, quinidine, ranolazine, dronedarone, felodipine, erythromycin, and azithromycin) may have increases in exposure compared with patients with normal renal function and no inhibitor use, since both pathways of rivaroxaban elimination are affected.; Single doses of warfarin and XARELTO resulted in an additive effect on factor Xa inhibition and PT. ; Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. ; NSAIDs are known to increase bleeding, and bleeding risk may be increased when NSAIDs are used concomitantly with XARELTO. ; Single doses of enoxaparin and XARELTO given concomitantly resulted in an additive effect on anti-factor Xa activity. ; Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs [see Warnings and Precautions (5.2)].; Concomitant aspirin use has been identified as an independent risk factor for major bleeding in efficacy trials. ; Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk. ; 
Conivaptan$Drug$DB00872$Simvastatin$Drug$DB00641$true$Increase_Interaction$
CYCLOSPORINE$Drug$DB00091$Aliskiren$Drug$DB01258$true$Caution_Interaction$Cyclosporin e : Avoid co-administration of cyclosporine with aliskiren.; Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or non-steroidal anti-inflammatory (NSAID) therapy may be at particular risk for developing acute renal failure on Tekamlo see Contraindications (4), Warnings and Precautions (5.2), Clinical Studies (14.2). ; The antihypertensive effect of aliskiren may be attenuated by NSAIDs.; Monitor serum potassium periodically in patients receiving aliskiren. ; Monitor renal function periodically in patients receiving aliskiren and NSAID therapy.; Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEI see Contraindications (4), Warnings and Precautions (5.2), and Clinical Studies (14.2), NSAIDs, or potassium supplements or potassium sparing diuretics.; Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function.; Itraconazole: Avoid co-administration of itraconazole with aliskiren see Clinical Pharmacology (12.3.; Non-Steroidal Anti-Inflammatory Agents(NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors with agents that affect the renin-angiotensin system, including aliskiren, may result in deterioration of renal function, including possible acute renal failure. ; Use Amturnide for patients not adequately controlled with any two of the following: aliskiren, dihydropyridine calcium channel blockers, and thiazide diuretics.; No drug interaction studies have been conducted with Tekamlo and other drugs, although studies with the individual aliskiren and amlodipine besylate components are described below.; Avoid concomitant use of aliskiren with cyclosporine or intraconazole see Drug Interactions (7).; When aliskiren was given with cyclosporine or itraconazole, the blood concentrations of aliskiren were significantly increased. ; 
CYCLOSPORINE$Drug$DB00091$Aliskiren$Drug$DB01258$true$Increase_Interaction$Cyclosporin e : Avoid co-administration of cyclosporine with aliskiren.; Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or non-steroidal anti-inflammatory (NSAID) therapy may be at particular risk for developing acute renal failure on Tekamlo see Contraindications (4), Warnings and Precautions (5.2), Clinical Studies (14.2). ; The antihypertensive effect of aliskiren may be attenuated by NSAIDs.; Monitor serum potassium periodically in patients receiving aliskiren. ; Monitor renal function periodically in patients receiving aliskiren and NSAID therapy.; Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEI see Contraindications (4), Warnings and Precautions (5.2), and Clinical Studies (14.2), NSAIDs, or potassium supplements or potassium sparing diuretics.; Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function.; Itraconazole: Avoid co-administration of itraconazole with aliskiren see Clinical Pharmacology (12.3.; Non-Steroidal Anti-Inflammatory Agents(NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors with agents that affect the renin-angiotensin system, including aliskiren, may result in deterioration of renal function, including possible acute renal failure. ; Use Amturnide for patients not adequately controlled with any two of the following: aliskiren, dihydropyridine calcium channel blockers, and thiazide diuretics.; No drug interaction studies have been conducted with Tekamlo and other drugs, although studies with the individual aliskiren and amlodipine besylate components are described below.; Avoid concomitant use of aliskiren with cyclosporine or intraconazole see Drug Interactions (7).; When aliskiren was given with cyclosporine or itraconazole, the blood concentrations of aliskiren were significantly increased. ; 
CYCLOSPORINE$Drug$DB00091$ATORVASTATIN$Drug$DB01076$true$Caution_Interaction$
CYCLOSPORINE$Drug$DB00091$DILTIAZEM$Drug$DB00343$true$Caution_Interaction$Tiazac capsules contain diltiazem hydrochloride in extended-release beads at doses of 120, 180, 240, 300, 360 and 420 mg.; Tiazac capsules contain diltiazem hydrochloride in extended-release beads at doses of 120, 180, 240, 300, 360 and 420 mg.; 
CYCLOSPORINE$Drug$DB00091$DILTIAZEM$Drug$DB00343$true$Increase_Interaction$Tiazac capsules contain diltiazem hydrochloride in extended-release beads at doses of 120, 180, 240, 300, 360 and 420 mg.; Tiazac capsules contain diltiazem hydrochloride in extended-release beads at doses of 120, 180, 240, 300, 360 and 420 mg.; 
CYCLOSPORINE$Drug$DB00091$Furosemide$Drug$DB00695$true$Specific_Interaction$
Dabigatran etexilate$Drug$DB06695$AMIODARONE$Drug$DB01118$true$Decrease_Interaction$
Dabigatran etexilate$Drug$DB06695$Dronedarone$Drug$DB04855$true$Caution_Interaction$When co-administered with dronedarone exposure to S-warfarin was slightly higher than when warfarin was administered alone. ; Exposure to dabigatran is higher when it is administered with dronedarone than when it is administered alone.; More patients experienced clinically significant INR elevations (  5) usually within 1 week after starting dronedarone vs. placebo in patients taking oral anticoagulants in ATHENA. ; Other P-gp substrates are expected to have increased exposure when co-administered with dronedarone.; Consider discontinuing digoxin. ; If digoxin treatment is continued, halve the dose of digoxin, monitor serum levels closely, and observe for toxicity [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].; 
Dabigatran etexilate$Drug$DB06695$Dronedarone$Drug$DB04855$true$Increase_Interaction$When co-administered with dronedarone exposure to S-warfarin was slightly higher than when warfarin was administered alone. ; Exposure to dabigatran is higher when it is administered with dronedarone than when it is administered alone.; More patients experienced clinically significant INR elevations (  5) usually within 1 week after starting dronedarone vs. placebo in patients taking oral anticoagulants in ATHENA. ; Other P-gp substrates are expected to have increased exposure when co-administered with dronedarone.; Consider discontinuing digoxin. ; If digoxin treatment is continued, halve the dose of digoxin, monitor serum levels closely, and observe for toxicity [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].; 
Darunavir$Drug$DB01264$ATORVASTATIN$Drug$DB01076$true$Caution_Interaction$
Digitoxin$Drug$DB01396$QUINIDINE$Drug$DB00908$true$Increase_Interaction$Quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine.; 
Digoxin$Drug$DB00390$Adenosine$Drug$DB00640$true$Specific_Interaction$
Digoxin$Drug$DB00390$Carvedilol$Drug$DB01136$true$Caution_Interaction$Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant subjects suffering from chronic vascular rejection. ; In about 30% of subjects, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed. ; Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG [see Clinical Pharmacology (12.5)].; Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.; Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly. ; 
Digoxin$Drug$DB00390$Diltiazem$Drug$DB00343$true$Caution_Interaction$
Digoxin$Drug$DB00390$Dofetilide$Drug$DB00204$true$Specific_Interaction$
Digoxin$Drug$DB00390$Dronedarone$Drug$DB04855$true$Specific_Interaction$
Digoxin$Drug$DB00390$Epoprostenol$Drug$DB01240$true$Increase_Interaction$Each vial of FLOLAN contains epoprostenol sodium equivalent to either 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) epoprostenol, 3.76 mg glycine, 2.93 mg sodium chloride, and 50 mg mannitol. ; 
Digoxin$Drug$DB00390$Nicardipine$Drug$DB00622$true$Caution_Interaction$CARDENE SR capsules for oral administration each contain 30 mg, 45 mg or 60 mg of nicardipine hydrochloride.; 
Digoxin$Drug$DB00390$NIFEDIPINE$Drug$DB01115$true$Caution_Interaction$
Digoxin$Drug$DB00390$NIFEDIPINE$Drug$DB01115$true$Increase_Interaction$
Digoxin$Drug$DB00390$TELMISARTAN$Drug$DB00966$true$Caution_Interaction$Lithium : Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. ; Digoxin : When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. ; Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) : In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible acute renal failure. ; The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.; Cases have also been reported with angiotensin II receptor antagonists including telmisartan. ; Avoid use of aliskiren with MICARDIS HCT in patients with renal impairment (GFR 60 mL/min).; It is, therefore, recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing telmisartan to avoid possible over- or under-digitalization.; Monitor renal function periodically in patients receiving telmisartan and NSAID therapy.; Because lithium should not be used with diuretics, the use of lithium with telmisartan and hydrochlorothiazide is not recommended.; 
Digoxin$Drug$DB00390$Torasemide$Drug$DB00214$true$Increase_Interaction$
Digoxin$Drug$DB00390$Verapamil$Drug$DB00661$true$Caution_Interaction$
DILTIAZEM$Drug$DB00343$Buspirone$Drug$DB00490$true$Increase_Interaction$
DILTIAZEM$Drug$DB00343$CARBAMAZEPINE$Drug$DB00564$true$Increase_Interaction$
DILTIAZEM$Drug$DB00343$Cimetidine$Drug$DB00501$true$Caution_Interaction$
DILTIAZEM$Drug$DB00343$Cimetidine$Drug$DB00501$true$Increase_Interaction$
DILTIAZEM$Drug$DB00343$Clonidine$Drug$DB00575$true$Caution_Interaction$
DILTIAZEM$Drug$DB00343$CYCLOSPORINE$Drug$DB00091$true$Specific_Interaction$
Diltiazem$Drug$DB00343$Digoxin$Drug$DB00390$true$Increase_Interaction$
DILTIAZEM$Drug$DB00343$Dronedarone$Drug$DB04855$true$Increase_Interaction$
DILTIAZEM$Drug$DB00343$MIDAZOLAM$Drug$DB00683$true$Increase_Interaction$
DILTIAZEM$Drug$DB00343$MIDAZOLAM$Drug$DB00683$true$Specific_Interaction$
DILTIAZEM$Drug$DB00343$QUINIDINE$Drug$DB00908$true$Increase_Interaction$Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent.; Each tablet of CARDIZEM contains 30 mg, 60 mg, 90 mg, or 120 mg diltiazem hydrochloride.; Tiazac capsules contain diltiazem hydrochloride in extended-release beads at doses of 120, 180, 240, 300, 360 and 420 mg.; Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. ; 
DILTIAZEM$Drug$DB00343$RIFAMPICIN$Drug$DB01045$true$Caution_Interaction$Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. ; 
DILTIAZEM$Drug$DB00343$SIMVASTATIN$Drug$DB00641$true$Increase_Interaction$&lt;item&gt;Also contains: colloidal silicon dioxide, D - C Yellow #10 Aluminum Lake, FD - C Blue #1 Aluminum Lake (30 mg and 90 mg), FD - C Yellow #6 Aluminum Lake (60 mg and 120 mg), hydroxypropyl cellulose, hypromellose, lactose, magnesium stearate, methylparaben, microcrystalline cellulose, and polyethylene glycol.; &lt;item&gt;Tiazac also contains: black iron oxide, D - C Red No. ; In a ten-subject randomized, open label, 4-way cross-over study, co-administration of diltiazem (120 mg BID diltiazem SR for 2 weeks) with a single 20 mg dose of lovastatin resulted in 3- to 4-fold increase in mean lovastatin AUC and Cmax versus lovastatin alone. ; Subjects with increased average steady-state exposures of diltiazem showed a greater fold increase in simvastatin exposure. ; This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second, or third degree AV block (22 of 10,119 patients, or 0.2%), 41% of these 22 patients were receiving concomitant -adrenoceptor antagonists versus 17% of the total group. ; In a healthy volunteer cross-over study (N 10), co-administration of a single 20 mg dose of simvastatin at the end of a 14 day regimen with 120 mg BID diltiazem SR resulted in a 5-fold increase in mean simvastatin AUC versus simvastatin alone. ; Computer-based simulations showed that at a daily dose of 480 mg of diltiazem, an 8- to 9-fold mean increase in simvastatin AUC can be expected. ; Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.; If co-administration of simvastatin with diltiazem is required, limit the daily doses of simvastatin to 10 mg and diltiazem to 240 mg.; In the same study, there was no significant change in 20 mg single dose pravastatin AUC and Cmax during diltiazem coadministration. ; 
DILTIAZEM$Drug$DB00343$TRIAZOLAM$Drug$DB00897$true$Increase_Interaction$
DILTIAZEM$Drug$DB00343$TRIAZOLAM$Drug$DB00897$true$Specific_Interaction$
DIPHENOXYLATE$Drug$DB01081$Digoxin$Drug$DB00390$true$Increase_Interaction$
Dipyridamole$Drug$DB00975$Adenosine$Drug$DB00640$true$Increase_Interaction$Drug Label for drug brand Persantine, containing dipyridamole.; 
Disopyramide$Drug$DB00280$QUINIDINE$Drug$DB00908$true$Decrease_Interaction$The average duration of treatment with encainide or flecainide in this study was 10 months.; 
Dobutamine$Drug$DB00841$NITROPRUSSIDE$Drug$DB00325$true$Specific_Interaction$Dextrose solutions without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.; Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.; 
DOXORUBICIN$Drug$DB00997$Verapamil$Drug$DB00661$true$Increase_Interaction$Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; Concentrations of verapamil may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or St John s Wort.; Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.; Verapamil therapy may increase serum levels of cyclosporin, sirolimus and tacrolimus.; When verapamil and colchicine are administered together, the potential inhibition of P-gp and/or CYP3A by verapamil may lead to increased exposure to colchicine (see PRECAUTIONS - Drug Interactions ).; There have been reports that verapamil may elevate the concentrations of the oral anti-diabetic glyburide.; Concentrations of doxorubicin may be increased by the administration of verapamil.; Verapamil therapy may inhibit the clearance and increase the plasma levels of theophylline.; 
Dronedarone$Drug$DB04855$Dabigatran etexilate$Drug$DB06695$true$Caution_Interaction$
Dronedarone$Drug$DB04855$Dabigatran etexilate$Drug$DB06695$true$Increase_Interaction$
Dronedarone$Drug$DB04855$Digoxin$Drug$DB00390$true$Increase_Interaction$Other CYP 2D6 substrates, including other beta-blockers, tricyclic antidepressants, and selective serotonin reuptake inhibitors (SSRIs) may have increased exposure upon co-administration with dronedarone [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].; Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of Torsade de Pointes, such as phenothiazine anti-psychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics; Give low doses of beta-blockers initially, and increase only after ECG verification of good tolerability. ; Dronedarone increased the exposure of propranolol and metoprolol. ; Sirolimus, tacrolimus, and other CYP3A substrates with narrow therapeutic range; Dronedarone can increase plasma concentrations of tacrolimus, sirolimus, and other CYP 3A substrates with a narrow therapeutic range when given orally. ; Dronedarone increased digoxin exposure by inhibiting the P-gp transporter. ; Monitor plasma concentrations and adjust dosage appropriately.; 
Dronedarone$Drug$DB04855$SIMVASTATIN$Drug$DB00641$true$Increase_Interaction$Concomitant use of strong CYP 3A inhibitors, such as ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, and ritonavir [see Drug Interactions (7.2)]; 
D-SORBITOL$Drug$DB01638$Polystyrene sulfonate$Drug$DB01344$true$Specific_Interaction$
ENALAPRIL$Drug$DB00584$LITHIUM$Drug$DB01356$true$Caution_Interaction$Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC.; Other Cardiovascular Agents: Enalapril has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions.; Potassium-sparing diuretics (e.g., spironolactone, triameterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. ; Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia they should be used with caution and with frequent monitoring of serum potassium.; In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. ; However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.; Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. ; It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.; Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. ; A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril and lithium and were reversible upon discontinuation of both drugs. ; Agents Increasing Serium Potassium: Enalapril attenuates diuretic-induced potassium loss. ; A few cases of lithium toxicity have been reported in patients receiving concomitant VASOTEC and lithium and were reversible upon discontinuation of both drugs. ; Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASERETIC.; 
Eplerenone$Drug$DB00700$ENALAPRIL$Drug$DB00584$true$Specific_Interaction$
Eplerenone$Drug$DB00700$LITHIUM$Drug$DB01356$true$Caution_Interaction$
Epoprostenol$Drug$DB01240$Digoxin$Drug$DB00390$true$Increase_Interaction$
Epoprostenol$Drug$DB01240$Furosemide$Drug$DB00695$true$Increase_Interaction$
ERYTHROMYCIN$Drug$DB00199$Cilostazol$Drug$DB01166$true$Increase_Interaction$PLETAL (cilostazol) tablet; 
ERYTHROMYCIN$Drug$DB00199$Digoxin$Drug$DB00390$true$Increase_Interaction$
ERYTHROMYCIN$Drug$DB00199$Felodipine$Drug$DB01023$true$Increase_Interaction$
ERYTHROMYCIN$Drug$DB00199$Losartan$Drug$DB00678$true$Increase_Interaction$Drug Label for drug brand Losartan Potassium, containing losartan potassium.; Drug Label for drug brand losartan potassium and hydrochlorothiazide, containing losartan potassium and hydrochlorothiazide.; 
ERYTHROMYCIN$Drug$DB00199$RIVAROXABAN$Drug$DB06228$true$Increase_Interaction$In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; 
ERYTHROMYCIN$Drug$DB00199$RIVAROXABAN$Drug$DB06228$true$Specific_Interaction$In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; 
Erythromycin$Drug$DB00199$Verapamil$Drug$DB00661$true$Increase_Interaction$Monitor renal function periodically in patients receiving trandolapril and NSAID therapy.; Phenobarbital therapy may increase verapamil clearance.; Verapamil may increase carbamazepine concentrations during combined therapy. ; &lt;main&gt;Trandolapril is the ethyl ester prodrug of a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, trandolaprilat. ; Therapy with rifampin may markedly reduce oral verapamil bioavailability. ; The antihypertensive effect of ACE inhibitors, including trandolapril may be attenuated by NSAIDs.; There have been reports that erythromycin and telithromycin may increase concentrations of verapamil.; 
Esmolol$Drug$DB00187$Digoxin$Drug$DB00390$true$Increase_Interaction$Concomitant use increases the risk of bradycardia.; &lt;item&gt;Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. ; (See clonidine, guanfacine, and moxonidine below.) ; &lt;item&gt;Anticholinesterases: BREVIBLOC prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium.; &lt;item&gt;Calcium channel antagonists: In patients with depressed myocardial function, use of BREVIBLOC with cardiodepressant calcium channel antagonists (e.g., verapamil) can lead to fatal cardiac arrests.; &lt;item&gt;Digitalis glycosides: Concomitant administration of digoxin and BREVIBLOC leads to an approximate 10% to 20% increase of digoxin blood levels at some time points. ; Both digoxin and beta blockers slow atrioventricular conduction and decrease heart rate. ; If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual.; Digoxin does not affect BREVIBLOC pharmacokinetics. ; 
Esmolol$Drug$DB00187$Furosemide$Drug$DB00695$true$Caution_Interaction$
Esmolol$Drug$DB00187$SUCCINYLCHOLINE$Drug$DB00202$true$Specific_Interaction$&lt;item&gt;Calcium channel antagonists: In patients with depressed myocardial function, use of BREVIBLOC with cardiodepressant calcium channel antagonists (e.g., verapamil) can lead to fatal cardiac arrests.; Digoxin does not affect BREVIBLOC pharmacokinetics. ; &lt;item&gt;Anticholinesterases: BREVIBLOC prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium.; (See clonidine, guanfacine, and moxonidine below.) ; &lt;item&gt;Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. ; Both digoxin and beta blockers slow atrioventricular conduction and decrease heart rate. ; Concomitant use increases the risk of bradycardia.; If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual.; &lt;item&gt;Digitalis glycosides: Concomitant administration of digoxin and BREVIBLOC leads to an approximate 10% to 20% increase of digoxin blood levels at some time points. ; 
ESOMEPRAZOLE$Drug$DB00736$Clopidogrel$Drug$DB00758$true$Specific_Interaction$PLAVIX (clopidogrel bisulfate) tablet, film coated; 
ETHANOL$Substance$DB00898$ACETYLSALICYLIC ACID$Drug$DB00945$true$Specific_Interaction$
Felodipine$Drug$DB01023$TACROLIMUS$Drug$DB00864$true$Caution_Interaction$
Felodipine$Drug$DB01023$TACROLIMUS$Drug$DB00864$true$Increase_Interaction$
FENTANYL$Drug$DB00813$AMIODARONE$Drug$DB01118$true$Specific_Interaction$Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.; John's Wort likely reduces amiodarone levels.; Fentanyl (CYP3A substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.; Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (CYP3A substrate) given for local anesthesia. ; Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone.; 
Fluconazole$Drug$DB00196$Losartan$Drug$DB00678$true$Increase_Interaction$Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration. ; Monitor renal function periodically in patients receiving losartan and NSAID therapy.; Therefore, serum lithium levels should be monitored carefully if lithium salts are to be co-administered with angiotensin II receptor antagonists.; Coadministration of losartan and phenobarbital led to a reduction of about 20% in the AUC of losartan and that of its active metabolite. ; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including losartan) may result in deterioration of renal function, including possible acute renal failure. ; Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration. ; As with other drugs which affect the excretion of sodium, lithium excretion may be reduced. ; Drug Label for drug brand losartan potassium and hydrochlorothiazide, containing losartan potassium and hydrochlorothiazide.; These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.; As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements).; Drug Label for drug brand Losartan Potassium, containing losartan potassium.; Lithium: As with other drugs which affect the excretion of sodium, lithium excretion may be reduced. ; When pregnancy is detected, losartan potassium and hydrochlorothiazide should be discontinued as soon as possible.; 
Fluconazole$Drug$DB00196$RIVAROXABAN$Drug$DB06228$true$Increase_Interaction$In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; 
Fluconazole$Drug$DB00196$RIVAROXABAN$Drug$DB06228$true$Specific_Interaction$In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; 
Fludrocortisone$Drug$DB00687$Midodrine$Drug$DB00211$true$Caution_Interaction$
Fosamprenavir$Drug$DB01319$ATORVASTATIN$Drug$DB01076$true$Caution_Interaction$
Furosemide$Drug$DB00695$ACETYLSALICYLIC ACID$Drug$DB00945$true$Specific_Interaction$
Furosemide$Drug$DB00695$CHLORAL HYDRATE$Drug$DB01563$true$Caution_Interaction$
Furosemide$Drug$DB00695$Corticotropin$Drug$DB01285$true$Specific_Interaction$
FUROSEMIDE$Drug$DB00695$Epoprostenol$Drug$DB01240$true$Increase_Interaction$Each vial of FLOLAN contains epoprostenol sodium equivalent to either 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) epoprostenol, 3.76 mg glycine, 2.93 mg sodium chloride, and 50 mg mannitol. ; 
Furosemide$Drug$DB00695$ETHACRYNIC ACID$Drug$DB00903$true$Specific_Interaction$LASIX tablets for oral administration contain furosemide as the active ingredient and the following inactive ingredients: lactose monohydrate NF, magnesium stearate NF, starch NF, talc USP, and colloidal silicon dioxide NF. ; 
Furosemide$Drug$DB00695$Metolazone$Drug$DB00524$true$Specific_Interaction$Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes (see WARNINGS).; When ZAROXOLYN Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. ; Thiazide diuretics have exacerbated or activated systemic lupus erythematosus and this possibility should be considered with ZAROXOLYN Tablets.; Dosage adjustments of other antihypertensives may be necessary.; Alcohol, Barbiturates, And Narcotics; 
Furosemide$Drug$DB00695$NOREPINEPHRINE$Drug$DB00368$true$Specific_Interaction$
Furosemide$Drug$DB00695$SUCCINYLCHOLINE$Drug$DB00202$true$Increase_Interaction$LASIX tablets for oral administration contain furosemide as the active ingredient and the following inactive ingredients: lactose monohydrate NF, magnesium stearate NF, starch NF, talc USP, and colloidal silicon dioxide NF. ; 
Furosemide$Drug$DB00695$TUBOCURARINE$Drug$DB01199$true$Specific_Interaction$LASIX tablets for oral administration contain furosemide as the active ingredient and the following inactive ingredients: lactose monohydrate NF, magnesium stearate NF, starch NF, talc USP, and colloidal silicon dioxide NF. ; 
GEMFIBROZIL$Drug$DB01241$Treprostinil$Drug$DB00374$true$Increase_Interaction$
GLYBURIDE$Drug$DB01016$Bosentan$Drug$DB00559$true$Caution_Interaction$T.A.P. is a component of the Tracleer Risk Evaluation and Mitigation Strategy (REMS). ; T.A.P. is a component of the Tracleer Risk Evaluation and Mitigation Strategy (REMS). ; 
GLYBURIDE$Drug$DB01016$BOSENTAN$Drug$DB00559$true$Specific_Interaction$T.A.P. is a component of the Tracleer Risk Evaluation and Mitigation Strategy (REMS). ; T.A.P. is a component of the Tracleer Risk Evaluation and Mitigation Strategy (REMS). ; 
GUANABENZ$Drug$DB00629$HYDROCHLOROTHIAZIDE$Drug$DB00999$true$Increase_Interaction$Moexipril and hydrochlorothiazide are effective treatments for hypertension. ; The recommended dosage range of moexipril is 7.5 to 30 mg daily, administered in a single or two divided doses one hour before meals, while hydrochlorothiazide is effective in a dosage of 12.5 to 50 mg daily.; Coadministration of propantheline or guanabenz increased the absorption of hydrochlorothiazide.; Moexipril has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, and cholesterol-lowering agents. ; In general, ACE inhibitors have less than additive effects with beta-adrenergic blockers, presumably because both work by inhibiting the renin-angiotensin system.; Therapy with any combination of moexipril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but regimens in which moexipril is combined with low doses of hydrochlorothiazide produce minimal effects on serum potassium. ; 
HALOPERIDOL$Drug$DB00502$QUINIDINE$Drug$DB00908$true$Increase_Interaction$
HYDROCHLOROTHIAZIDE$Drug$DB00999$Amphotericin B$Drug$DB00681$true$Specific_Interaction$Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect.; Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine (an effect attributed to potassium loss), consequently caution should be observed in patients undergoing surgery.; Thiazides may add to or potentiate the action of other antihypertensive drugs. ; Lithium generally should not be given with diuretics because they reduce its renal clearance and increase the risk of lithium toxicity. ; Thiazides have been shown to decrease arterial responsiveness to norepinephrine (an effect attributed to loss of sodium). ; Read circulars for lithium preparations before use of such concomitant therapy with DYAZIDE.; 
Hydrochlorothiazide$Drug$DB00999$Dofetilide$Drug$DB00204$true$Increase_Interaction$
HYDROCHLOROTHIAZIDE$Drug$DB00999$METHYLDOPA$Drug$DB00968$true$Specific_Interaction$
HYDROCHLOROTHIAZIDE$Drug$DB00999$NOREPINEPHRINE$Drug$DB00368$true$Specific_Interaction$Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with ALDACTAZIDE.; Pressor amines (e.g., norepinephrine): Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. ; Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant may result.; Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia, may occur.; Lithium: Lithium generally should not be given with diuretics. ; Combination of NSAIDs, e.g., indomethacin, with potassium-sparing diuretics has been associated with severe hyperkalemia. ; Nonsteroidal anti-inflammatory drugs (NSAIDs): In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics. ; Therefore, when ALDACTAZIDE and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.; Digoxin: Spironolactone has been shown to increase the half-life of digoxin. ; Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.; 
INDINAVIR$Drug$DB00224$AMIODARONE$Drug$DB01118$true$Increase_Interaction$Loratadine, a non-sedating antihistaminic, is metabolized primarily by CYP3A. ; A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L. ; Consider monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy.; Since amiodarone is a substrate for CYP3A and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone. ; 
INDOMETHACIN$Drug$DB00328$Digoxin$Drug$DB00390$true$Increase_Interaction$
INDOMETHACIN$Drug$DB00328$Furosemide$Drug$DB00695$true$Caution_Interaction$
INDOMETHACIN$Drug$DB00328$Furosemide$Drug$DB00695$true$Specific_Interaction$
INDOMETHACIN$Drug$DB00328$Triamterene$Drug$DB00384$true$Specific_Interaction$Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including Dyrenium. ; 
Irbesartan$Drug$DB01029$HYDROCHLOROTHIAZIDE$Drug$DB00999$true$Specific_Interaction$
Irbesartan$Drug$DB01029$NIFEDIPINE$Drug$DB01115$true$Specific_Interaction$
Irbesartan$Drug$DB01029$TOLBUTAMIDE$Drug$DB01124$true$Specific_Interaction$
Iron$Drug$DB01592$Acetohydroxamic Acid$Drug$DB00551$true$Specific_Interaction$&lt;item&gt;AHA is weakly acidic, highly soluble in water, and chelates metals - notably iron. ; 
Isosorbide Mononitrate$Drug$DB01020$Sildenafil$Drug$DB00203$true$Specific_Interaction$
Ketoconazole$Drug$DB01026$BOSENTAN$Drug$DB00559$true$Increase_Interaction$Coadministration of bosentan 125 mg twice daily and ketoconazole, a potent CYP3A inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold in normal volunteers. ; Coadministration of bosentan 500 mg twice daily for 6 days in normal volunteers decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A substrate) by 29 and 38%, respectively. ; In normal volunteers, coadministration of multiple doses of 125 mg twice daily bosentan and 80 mg three times daily sildenafil resulted in a reduction of sildenafil plasma concentrations by 63% and increased bosentan plasma concentrations by 50%. ; No dose adjustment of Tracleer is necessary, but increased effects of Tracleer should be considered.; Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.; Clinical experience with concomitant administration of Tracleer and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among Tracleer- and placebo-treated patients.; 7.11 Digoxin, Nimodipine, and Losartan; 
Ketoconazole$Drug$DB01026$CONIVAPTAN$Drug$DB00872$true$Increase_Interaction$
Ketoconazole$Drug$DB01026$Dofetilide$Drug$DB00204$true$Caution_Interaction$
Ketoconazole$Drug$DB01026$Dofetilide$Drug$DB00204$true$Increase_Interaction$
Ketoconazole$Drug$DB01026$Dofetilide$Drug$DB00204$true$Specific_Interaction$
Ketoconazole$Drug$DB01026$Eplerenone$Drug$DB00700$true$Increase_Interaction$
Ketoconazole$Drug$DB01026$RIVAROXABAN$Drug$DB06228$true$Increase_Interaction$Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; 
Ketoconazole$Drug$DB01026$RIVAROXABAN$Drug$DB06228$true$Specific_Interaction$Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; 
Labetalol$Drug$DB00598$Nitroglycerin$Drug$DB00727$true$Specific_Interaction$
Lansoprazole$Drug$DB00448$Clopidogrel$Drug$DB00758$true$Specific_Interaction$
Levothyroxine$Drug$DB00451$Tirofiban$Drug$DB00775$true$Decrease_Interaction$
Lisinopril$Drug$DB00722$INDOMETHACIN$Drug$DB00328$true$Decrease_Interaction$In some patients with compromised renal function (e.g., elderly patients or patients who are volume-depleted including those on diuretic therapy) who are being treated with non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors, the co-administration of angiotensin II receptor antagonists or ACE inhibitors may result in a further deterioration of renal function, including possible acute renal failure. ; These interactions should be considered in patients taking NSAIDS including selective COX-2 inhibitors concomitantly with diuretics and angiotensin II antagonists or ACE inhibitors. ; In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.; This interaction should be given consideration in patients taking NSAIDs or selective COX-2 inhibitors concomitantly with ACE inhibitors.; Closely monitor blood pressure, renal function, and electrolytes in patients on PRINIVIL and other agents that affect the RAAS. ; Dual Blockade of the Renin-angiotensin-aldosterone System: Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with angiotensin receptor blockers, ACE inhibitors, or direct renin inhibitors (such as aliskiren) is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. ; Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including PRINIVIL. ; Avoid use of aliskiren with PRINIVIL in patients with renal impairment (GFR &lt;60ml/min).; Do not coadminister aliskiren with PRINIVIL in patients with diabetes. ; 
Lisinopril$Drug$DB00722$LITHIUM$Drug$DB01356$true$Caution_Interaction$Potassium-sparing agents should generally not be used in patients with heart failure who are receiving ZESTRIL.; Avoid use of aliskiren with ZESTORETIC in patients with renal impairment (GFR &lt; 60 ml/min).; Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. ; Use of lisinopril with potassium-sparing diuretics (eg, spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. ; Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including ZESTRIL.; Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor. ; It is recommended that serum lithium levels be monitored frequently if lisinopril is administered concomitantly with lithium.; It is recommended that serum lithium levels be monitored frequently if ZESTRIL is administered concomitantly with lithium.; Other Agents: Lisinopril has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions. ; Use of ZESTRIL with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. ; Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. ; No meaningful clinically important pharmacokinetic interactions occurred when lisinopril was used concomitantly with propranolol, digoxin, or hydrochlorothiazide. ; Agents Increasing Serum Potassium: Lisinopril attenuates potassium loss caused by thiazide-type diuretics. ; Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. ; Therefore, if concomitant use of these agents is indicated, because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.; 
LITHIUM$Drug$DB01356$Benazepril$Drug$DB00542$true$Caution_Interaction$Lotensin is also contraindicated in patients with a history of angioedema with or without previous ACE inhibitor treatment.; 
LITHIUM$Drug$DB01356$Candesartan$Drug$DB00796$true$Increase_Interaction$ATACAND HCT is contraindicated in patients who are hypersensitive to candesartan, to hydrochlorothiazide or to other sulfonamide-derived drugs.; 
LITHIUM$Drug$DB01356$ENALAPRIL$Drug$DB00584$true$Increase_Interaction$A few cases of lithium toxicity have been reported in patients receiving concomitant VASOTEC and lithium and were reversible upon discontinuation of both drugs. ; Agents Increasing Serium Potassium: Enalapril attenuates diuretic-induced potassium loss. ; Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia they should be used with caution and with frequent monitoring of serum potassium.; Potassium-sparing diuretics (e.g., spironolactone, triameterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. ; A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril and lithium and were reversible upon discontinuation of both drugs. ; Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. ; Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC.; Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASERETIC.; In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. ; Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. ; However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.; Other Cardiovascular Agents: Enalapril has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions.; It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.; 
LITHIUM$Drug$DB01356$Telmisartan$Drug$DB00966$true$Caution_Interaction$Avoid use of aliskiren with MICARDIS HCT in patients with renal impairment (GFR 60 mL/min).; The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.; Because lithium should not be used with diuretics, the use of lithium with telmisartan and hydrochlorothiazide is not recommended.; Digoxin : When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. ; It is, therefore, recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing telmisartan to avoid possible over- or under-digitalization.; Lithium : Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. ; Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) : In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible acute renal failure. ; Cases have also been reported with angiotensin II receptor antagonists including telmisartan. ; Monitor renal function periodically in patients receiving telmisartan and NSAID therapy.; 
LITHIUM$Drug$DB01356$Verapamil$Drug$DB00661$true$Specific_Interaction$Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy; ; Patients receiving both drugs must be monitored carefully.; Verapamil therapy may increase serum levels of cyclosporine.; clearance of verapamil was either reduced or unchanged.; Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; The interaction between cimetidine and chronically administered verapamil has not been studied. ; Therapy with rifampin may markedly reduce oral verapamil bioavailability.; This may produce carbamazepine side effects such as diplopia, headache, ataxia, or dizziness.; lithium levels have been observed sometimes to increase, sometimes to decrease, and sometimes to be unchanged. ; However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium. ; Verapamil therapy may increase carbamazepine concentrations during combined therapy. ; Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels. ; Phenobarbital therapy may increase verapamil clearance.; 
Lopinavir$Drug$DB01601$ATORVASTATIN$Drug$DB01076$true$Caution_Interaction$
LORATADINE$Drug$DB00455$AMIODARONE$Drug$DB01118$true$Specific_Interaction$Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone. ; Cimetidine inhibits CYP3A and can increase serum amiodarone levels.; Do not take grapefruit juice during treatment with amiodarone.; QT interval prolongation and TdP have been reported with the co-administration of trazodone and amiodarone.; Trazodone, an antidepressant, is metabolized primarily by CYP3A. ; QT interval prolongation and TdP have been reported with the co-administration of loratadine and amiodarone.; 
Losartan$Drug$DB00678$HYDROCHLOROTHIAZIDE$Drug$DB00999$true$Specific_Interaction$Losartan, administered for 12 days, did not affect the pharmacokinetics or pharmacodynamics of a single dose of warfarin. ; 
Losartan$Drug$DB00678$RIFAMPICIN$Drug$DB01045$true$Decrease_Interaction$Drug Label for drug brand Losartan Potassium, containing losartan potassium.; Drug Label for drug brand losartan potassium and hydrochlorothiazide, containing losartan potassium and hydrochlorothiazide.; 
Metoclopramide$Drug$DB01233$Digoxin$Drug$DB00390$true$Decrease_Interaction$
Metolazone$Drug$DB00524$Furosemide$Drug$DB00695$true$Specific_Interaction$FORMULATIONS BIOEQUIVALENT TO ZAROXOLYN AND FORMULATIONS BIOEQUIVALENT TO MYKROX SHOULD NOT BE INTERCHANGED FOR ONE ANOTHER.; 
Metolazone$Drug$DB00524$NOREPINEPHRINE$Drug$DB00368$true$Specific_Interaction$Accordingly, it may be advisable to discontinue ZAROXOLYN three days before elective surgery.; Efficacy may be decreased due to urinary alkalizing effect of metolazone.; Insulin And Oral Antidiabetic Agents; Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.; Inactive Ingredients: Magnesium stearate, microcrystalline cellulose and dye: 2 mg-D - C Red No. ; May decrease the antihypertensive effects of ZAROXOLYN Tablets.; Salicylates And Other Non-Steroidal Anti-Inflammatory Drugs; 
Metoprolol$Drug$DB00264$Clonidine$Drug$DB00575$true$Caution_Interaction$Metoprolol tartrate USP is ( )-1-(Isopropylamino)-3- p -(2-methoxyethyl)phenoxy -2-propanol L-(+)-tartrate (2:1) salt, and its structural formula is; 
Metyrosine$Drug$DB00765$Ethanol$Substance$DB00898$true$Specific_Interaction$DEMSER (metyrosine) capsule; 
Metyrosine$Drug$DB00765$HALOPERIDOL$Drug$DB00502$true$Specific_Interaction$
MIDAZOLAM$Drug$DB00683$DILTIAZEM$Drug$DB00343$true$Increase_Interaction$
Midodrine$Drug$DB00211$Fludrocortisone$Drug$DB00687$true$Caution_Interaction$
NIFEDIPINE$Drug$DB01115$Cimetidine$Drug$DB00501$true$Caution_Interaction$These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients on concomitant beta blockers.; These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients on concomitant beta blockers.; 
NIFEDIPINE$Drug$DB01115$Cimetidine$Drug$DB00501$true$Increase_Interaction$These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients on concomitant beta blockers.; These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients on concomitant beta blockers.; 
NIFEDIPINE$Drug$DB01115$Digoxin$Drug$DB00390$true$Increase_Interaction$
NIFEDIPINE$Drug$DB01115$QUINIDINE$Drug$DB00908$true$Decrease_Interaction$
Nisoldipine$Drug$DB00401$PHENYTOIN$Drug$DB00252$true$Caution_Interaction$SULAR is contraindicated in patients with known hypersensitivity to dihydropyridine calcium channel blockers.; 
Nitroglycerin$Drug$DB00727$ACETYLSALICYLIC ACID$Drug$DB00945$true$Specific_Interaction$
NITROGLYCERIN$Drug$DB00727$Alteplase$Drug$DB00009$true$Caution_Interaction$
Nitroglycerin$Drug$DB00727$Sildenafil$Drug$DB00203$true$Specific_Interaction$
Penbutolol$Drug$DB01359$ETHANOL$Substance$DB00898$true$Specific_Interaction$
Penbutolol$Drug$DB01359$LIDOCAINE PATCH$Drug$DB05291$true$Decrease_Interaction$
Pentoxifylline$Drug$DB00806$Captopril$Drug$DB01197$true$Specific_Interaction$Drug Label for drug brand Trental, containing pentoxifylline.; 
Pentoxifylline$Drug$DB00806$NIFEDIPINE$Drug$DB01115$true$Specific_Interaction$Drug Label for drug brand Trental, containing pentoxifylline.; 
Pentoxifylline$Drug$DB00806$THEOPHYLLINE$Drug$DB00277$true$Increase_Interaction$Drug Label for drug brand Trental, containing pentoxifylline.; 
PHENOBARBITAL$Drug$DB01174$Losartan$Drug$DB00678$true$Decrease_Interaction$Drug Label for drug brand losartan potassium and hydrochlorothiazide, containing losartan potassium and hydrochlorothiazide.; Drug Label for drug brand Losartan Potassium, containing losartan potassium.; 
PHENOBARBITAL$Drug$DB01174$Verapamil$Drug$DB00661$true$Decrease_Interaction$Inhalation Anesthetics: Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.; &lt;main&gt;Trandolapril is the ethyl ester prodrug of a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, trandolaprilat. ; Monitor renal function periodically in patients receiving trandolapril and NSAID therapy.; Patients receiving both drugs must be monitored carefully.; Phenobarbital therapy may increase verapamil clearance.; Phenobarbital: Phenobarbital therapy may increase verapamil clearance.; Cyclosporine: Verapamil therapy may increase serum levels of cyclosporine.; There have been reports that erythromycin and telithromycin may increase concentrations of verapamil.; When used concomitantly, inhalation anesthetics and calcium channel blocking agents, such as verapamil, should each be titrated carefully to avoid excessive cardiovascular depression.; Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; Neuromuscular Blocking Agents: Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). ; Therapy with rifampin may markedly reduce oral verapamil bioavailability. ; Verapamil therapy may increase serum levels of cyclosporine.; Carbamazepine: Verapamil therapy may increase carbamazepine concentrations during combined therapy. ; It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.; The antihypertensive effect of ACE inhibitors, including trandolapril may be attenuated by NSAIDs.; Verapamil therapy may increase carbamazepine concentrations during combined therapy. ; Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). ; Rifampin: Therapy with rifampin may markedly reduce oral verapamil bioavailability.; This may produce carbamazepine side effects such as diplopia, headache, ataxia, or dizziness.; lithium levels have been observed sometimes to increase, sometimes to decrease, and sometimes to be unchanged. ; Verapamil may increase carbamazepine concentrations during combined therapy. ; Verapamil may inhibit the clearance and increase the plasma levels of theophylline.; When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, should be titrated carefully to avoid excessive cardiovascular depression.; Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy; ; 
Phenoxybenzamine$Drug$DB00925$Norepinephrine$Drug$DB00368$true$Specific_Interaction$Drug Label for drug brand Dibenzyline, containing Phenoxybenzamine Hydrochloride.; 
Phenoxybenzamine$Drug$DB00925$Reserpine$Drug$DB00206$true$Specific_Interaction$Drug Label for drug brand Dibenzyline, containing Phenoxybenzamine Hydrochloride.; 
Phenytoin$Drug$DB00252$AMIODARONE$Drug$DB01118$true$Decrease_Interaction$There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone. ; If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity.; Phenytoin decreases serum amiodarone levels. ; Phenytoin decreases serum amiodarone levels. ; Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity. ; Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. ; Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days. ; NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment.; Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone. ; Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. ; Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days. ; If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity.; NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment.; Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone. ; Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. ; Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity. ; Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. ; On administration of oral amiodarone, review the need for digitalis therapy and reduce the dose of digitalis by approximately 50% or discontinue digitalis. ; On administration of oral amiodarone, review the need for digitalis therapy and reduce the dose of digitalis by approximately 50% or discontinue digitalis. ; There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone. ; 
PHENYTOIN$Drug$DB00252$AMIODARONE$Drug$DB01118$true$Increase_Interaction$There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone. ; If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity.; Phenytoin decreases serum amiodarone levels. ; Phenytoin decreases serum amiodarone levels. ; Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity. ; Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. ; Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days. ; NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment.; Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone. ; Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. ; Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days. ; If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity.; NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment.; Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone. ; Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. ; Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity. ; Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. ; On administration of oral amiodarone, review the need for digitalis therapy and reduce the dose of digitalis by approximately 50% or discontinue digitalis. ; On administration of oral amiodarone, review the need for digitalis therapy and reduce the dose of digitalis by approximately 50% or discontinue digitalis. ; There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone. ; 
PHENYTOIN$Drug$DB00252$Furosemide$Drug$DB00695$true$Decrease_Interaction$
PHENYTOIN$Drug$DB00252$Furosemide$Drug$DB00695$true$Specific_Interaction$
PHENYTOIN$Drug$DB00252$LIDOCAINE PATCH$Drug$DB05291$true$Specific_Interaction$Lidocaine hydrochloride is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. ; 
Polystyrene sulfonate$Drug$DB01344$Levothyroxine$Drug$DB00451$true$Decrease_Interaction$
Polystyrene sulfonate$Drug$DB01344$LITHIUM$Drug$DB01356$true$Decrease_Interaction$
POTASSIUM$Substance$DB01345$Spironolactone$Drug$DB00421$true$Specific_Interaction$
Prazosin$Drug$DB00457$ETHANOL$Substance$DB00898$true$Caution_Interaction$
Probenecid$Drug$DB01032$Torasemide$Drug$DB00214$true$Specific_Interaction$
PROCAINAMIDE$Drug$DB01035$AMIODARONE$Drug$DB01118$true$Increase_Interaction$Phenytoin decreases serum amiodarone levels. ; Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. ; NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment.; Reserve the combination of amiodarone with other antiarrhythmic therapy to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone. ; Use amiodarone with caution in patients receiving -receptor blocking agents (e.g., propranolol, a CYP3A inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A substrate, and diltiazem, a CYP3A inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block, if necessary, amiodarone can continue to be used after insertion of a pacemaker in patients with severe bradycardia or sinus arrest.; Reduce quinidine and procainamide doses by one-third when either is administered with amiodarone.; Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity. ; In general, initiate any added antiarrhythmic drug at a lower than usual dose and monitor the patient carefully.; Review the continued need for the other antiarrhythmic agent after the effects of amiodarone have been established, and attempt discontinuation. ; There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone. ; Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. ; In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.; On administration of oral amiodarone, review the need for digitalis therapy and reduce the dose of digitalis by approximately 50% or discontinue digitalis. ; Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days. ; If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity.; &lt;item&gt;Hypotension: Treat initially by slowing the infusion, additional standard therapy may be needed, including the following: vasopressor drugs, positive inotropic agents, and volume expansion.(5.1); Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone. ; If the treatment is continued, carefully monitor these patients for adverse effects, especially for conduction disturbances and exacerbation of tachyarrhythmias. ; Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone, adjust the dose of flecainide when these drugs are administered concomitantly. ; 
Propantheline$Drug$DB00782$Digoxin$Drug$DB00390$true$Increase_Interaction$
Propantheline$Drug$DB00782$HYDROCHLOROTHIAZIDE$Drug$DB00999$true$Increase_Interaction$In general, ACE inhibitors have less than additive effects with beta-adrenergic blockers, presumably because both work by inhibiting the renin-angiotensin system.; Moexipril has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, and cholesterol-lowering agents. ; Therapy with any combination of moexipril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but regimens in which moexipril is combined with low doses of hydrochlorothiazide produce minimal effects on serum potassium. ; Moexipril and hydrochlorothiazide are effective treatments for hypertension. ; Coadministration of propantheline or guanabenz increased the absorption of hydrochlorothiazide.; The recommended dosage range of moexipril is 7.5 to 30 mg daily, administered in a single or two divided doses one hour before meals, while hydrochlorothiazide is effective in a dosage of 12.5 to 50 mg daily.; 
Propranolol$Drug$DB00571$Verapamil$Drug$DB00661$true$Increase_Interaction$As with other ACE inhibitors, patients on diuretics, especially those on recently instituted diuretic therapy, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with TARKA. ; Drug interaction studies have indicated that the maximum concentrations of metoprolol and propanolol are increased after the administration of verapamil. ; Closely monitor blood pressure, renal function and electrolytes in patients on TARKA and other agents that affect the RAS.; Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.; Avoid use of aliskiren with TARKA in patients with renal impairment (GFR 60 ml/min).; The use of verapamil in combination with a beta-adrenergic blocker should be used only with caution, and close monitoring.; Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction, and/or cardiac contractility. ; Do not co-administer aliskiren with TARKA in patients with diabetes. ; If it is not possible to discontinue the diuretic, the starting dose of TARKA should be reduced (see DOSAGE AND ADMINISTRATION ). ; The possibility of exacerbation of hypotensive effects with TARKA may be minimized by either discontinuing the diuretic or cautiously increasing salt intake prior to initiation of treatment with TARKA. ; 
Quinapril$Drug$DB00881$TETRACYCLINE$Drug$DB00759$true$Caution_Interaction$ACCURETIC and lithium should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.; Simultaneous administration of tetracycline with quinapril reduced the absorption of tetracycline by approximately 28% to 37%, possibly due to the high magnesium content in quinapril tablets. ; Nitritoid reactions (symptoms include facial flushing, nausea, vomiting, and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy.; This interaction should be considered if coprescribing quinapril and tetracycline or other drugs that interact with magnesium.; Because renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity is presumably raised further when, as in therapy with ACCURETIC, a thiazide diuretic is coadministered with the ACE inhibitor. ; Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ; 
Quinapril$Drug$DB00881$TETRACYCLINE$Drug$DB00759$true$Decrease_Interaction$ACCURETIC and lithium should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.; Simultaneous administration of tetracycline with quinapril reduced the absorption of tetracycline by approximately 28% to 37%, possibly due to the high magnesium content in quinapril tablets. ; Nitritoid reactions (symptoms include facial flushing, nausea, vomiting, and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy.; This interaction should be considered if coprescribing quinapril and tetracycline or other drugs that interact with magnesium.; Because renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity is presumably raised further when, as in therapy with ACCURETIC, a thiazide diuretic is coadministered with the ACE inhibitor. ; Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ; 
QUINIDINE$Drug$DB00908$AMIODARONE$Drug$DB01118$true$Increase_Interaction$Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. ; Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days. ; Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity. ; NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment.; Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone. ; Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone, adjust the dose of flecainide when these drugs are administered concomitantly. ; In general, initiate any added antiarrhythmic drug at a lower than usual dose and monitor the patient carefully.; On administration of oral amiodarone, review the need for digitalis therapy and reduce the dose of digitalis by approximately 50% or discontinue digitalis. ; Reserve the combination of amiodarone with other antiarrhythmic therapy to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone. ; There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone. ; Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. ; If the treatment is continued, carefully monitor these patients for adverse effects, especially for conduction disturbances and exacerbation of tachyarrhythmias. ; Reduce quinidine and procainamide doses by one-third when either is administered with amiodarone.; &lt;item&gt;Hypotension: Treat initially by slowing the infusion, additional standard therapy may be needed, including the following: vasopressor drugs, positive inotropic agents, and volume expansion.(5.1); Review the continued need for the other antiarrhythmic agent after the effects of amiodarone have been established, and attempt discontinuation. ; Use amiodarone with caution in patients receiving -receptor blocking agents (e.g., propranolol, a CYP3A inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A substrate, and diltiazem, a CYP3A inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block, if necessary, amiodarone can continue to be used after insertion of a pacemaker in patients with severe bradycardia or sinus arrest.; In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.; If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity.; Phenytoin decreases serum amiodarone levels. ; 
QUINIDINE$Drug$DB00908$Cimetidine$Drug$DB00501$true$Increase_Interaction$
QUINIDINE$Drug$DB00908$Dabigatran etexilate$Drug$DB06695$true$Increase_Interaction$
QUINIDINE$Drug$DB00908$Digoxin$Drug$DB00390$true$Increase_Interaction$Quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine.; 
QUINIDINE$Drug$DB00908$NIFEDIPINE$Drug$DB01115$true$Decrease_Interaction$
QUINIDINE$Drug$DB00908$PROCAINAMIDE$Drug$DB01035$true$Increase_Interaction$
QUINIDINE$Drug$DB00908$Verapamil$Drug$DB00661$true$Increase_Interaction$Concomitant administration of R verapamil can decrease the clearance of paclitaxel.; Alcohol: Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol. ; Quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine.; Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; There has been a report of increased quinidine levels during verapamil therapy.; Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent.; A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.; The electrophysiologic effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; The interaction between cimetidine and chronically administered verapamil has not been studied. ; Aspirin: In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.; Verapamil significantly counteracted the effects of quinidine on AV conduction. ; In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; Cimetidine: The interaction between cimetidine and chronically administered verapamil has not been studied. ; Grapefruit Juice: Grapefruit juice may significantly increase concentrations of verapamil. ; Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.; 
QUINIDINE$Drug$DB00908$Verapamil$Drug$DB00661$true$Specific_Interaction$Concomitant administration of R verapamil can decrease the clearance of paclitaxel.; Alcohol: Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol. ; Quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine.; Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; There has been a report of increased quinidine levels during verapamil therapy.; Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent.; A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.; The electrophysiologic effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; The interaction between cimetidine and chronically administered verapamil has not been studied. ; Aspirin: In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.; Verapamil significantly counteracted the effects of quinidine on AV conduction. ; In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; Cimetidine: The interaction between cimetidine and chronically administered verapamil has not been studied. ; Grapefruit Juice: Grapefruit juice may significantly increase concentrations of verapamil. ; Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.; 
Ramipril$Drug$DB00178$TELMISARTAN$Drug$DB00966$true$Increase_Interaction$When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.; Warfarin : Telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration, this decrease did not result in a change in International Normalized Ratio (INR).; &lt;item&gt;Antidiabetic drugs (oral agents and insulin) : Dosage adjustment of the antidiabetic drug may be required.; In contrast, Cmax and AUC of telmisartan decrease by 31% and 16%, respectively. ; Ramipril and Ramiprilat : Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. ; Other Drugs : Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide or ibuprofen. ; &lt;item&gt;Alcohol, barbiturates, or narcotics : Potentiation of orthostatic hypotension may occur.; 
Reserpine$Drug$DB00206$QUINIDINE$Drug$DB00908$true$Caution_Interaction$
RIFAMPICIN$Drug$DB01045$AMIODARONE$Drug$DB01118$true$Decrease_Interaction$Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (CYP3A substrate) given for local anesthesia. ; John's Wort likely reduces amiodarone levels.; Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.; Fentanyl (CYP3A substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.; Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone.; 
RIFAMPICIN$Drug$DB01045$Bisoprolol$Drug$DB00612$true$Decrease_Interaction$
RIFAMPICIN$Drug$DB01045$BOSENTAN$Drug$DB00559$true$Decrease_Interaction$Caution should be exercised if tacrolimus and Tracleer are used together.; The effect of Tracleer on rifampin levels has not been assessed. ; Caution should be exercised if tacrolimus and Tracleer are used together.; The effect of Tracleer on rifampin levels has not been assessed. ; When consideration of the potential benefits, and known and unknown risks leads to concomitant use, measure serum aminotransferases weekly for the first 4 weeks before reverting to normal monitoring.; Coadministration of bosentan and rifampin in normal volunteers resulted in a mean 6-fold increase in bosentan trough levels after the first concomitant dose (likely due to inhibition of OATP by rifampin), but about a 60% decrease in bosentan levels at steady-state. ; Coadministration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals. ; Coadministration of tacrolimus and Tracleer has not been studied in humans. ; Coadministration of bosentan and rifampin in normal volunteers resulted in a mean 6-fold increase in bosentan trough levels after the first concomitant dose (likely due to inhibition of OATP by rifampin), but about a 60% decrease in bosentan levels at steady-state. ; Coadministration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals. ; Coadministration of tacrolimus and Tracleer has not been studied in humans. ; Patients using CYP3A-metabolized statins should have cholesterol levels monitored after Tracleer is initiated to see whether the statin dose needs adjustment.; Patients using CYP3A-metabolized statins should have cholesterol levels monitored after Tracleer is initiated to see whether the statin dose needs adjustment.; When consideration of the potential benefits, and known and unknown risks leads to concomitant use, measure serum aminotransferases weekly for the first 4 weeks before reverting to normal monitoring.; 
RIFAMPICIN$Drug$DB01045$BOSENTAN$Drug$DB00559$true$Increase_Interaction$Caution should be exercised if tacrolimus and Tracleer are used together.; The effect of Tracleer on rifampin levels has not been assessed. ; Caution should be exercised if tacrolimus and Tracleer are used together.; The effect of Tracleer on rifampin levels has not been assessed. ; When consideration of the potential benefits, and known and unknown risks leads to concomitant use, measure serum aminotransferases weekly for the first 4 weeks before reverting to normal monitoring.; Coadministration of bosentan and rifampin in normal volunteers resulted in a mean 6-fold increase in bosentan trough levels after the first concomitant dose (likely due to inhibition of OATP by rifampin), but about a 60% decrease in bosentan levels at steady-state. ; Coadministration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals. ; Coadministration of tacrolimus and Tracleer has not been studied in humans. ; Coadministration of bosentan and rifampin in normal volunteers resulted in a mean 6-fold increase in bosentan trough levels after the first concomitant dose (likely due to inhibition of OATP by rifampin), but about a 60% decrease in bosentan levels at steady-state. ; Coadministration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals. ; Coadministration of tacrolimus and Tracleer has not been studied in humans. ; Patients using CYP3A-metabolized statins should have cholesterol levels monitored after Tracleer is initiated to see whether the statin dose needs adjustment.; Patients using CYP3A-metabolized statins should have cholesterol levels monitored after Tracleer is initiated to see whether the statin dose needs adjustment.; When consideration of the potential benefits, and known and unknown risks leads to concomitant use, measure serum aminotransferases weekly for the first 4 weeks before reverting to normal monitoring.; 
RIFAMPICIN$Drug$DB01045$BOSENTAN$Drug$DB00559$true$Specific_Interaction$Caution should be exercised if tacrolimus and Tracleer are used together.; The effect of Tracleer on rifampin levels has not been assessed. ; Caution should be exercised if tacrolimus and Tracleer are used together.; The effect of Tracleer on rifampin levels has not been assessed. ; When consideration of the potential benefits, and known and unknown risks leads to concomitant use, measure serum aminotransferases weekly for the first 4 weeks before reverting to normal monitoring.; Coadministration of bosentan and rifampin in normal volunteers resulted in a mean 6-fold increase in bosentan trough levels after the first concomitant dose (likely due to inhibition of OATP by rifampin), but about a 60% decrease in bosentan levels at steady-state. ; Coadministration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals. ; Coadministration of tacrolimus and Tracleer has not been studied in humans. ; Coadministration of bosentan and rifampin in normal volunteers resulted in a mean 6-fold increase in bosentan trough levels after the first concomitant dose (likely due to inhibition of OATP by rifampin), but about a 60% decrease in bosentan levels at steady-state. ; Coadministration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals. ; Coadministration of tacrolimus and Tracleer has not been studied in humans. ; Patients using CYP3A-metabolized statins should have cholesterol levels monitored after Tracleer is initiated to see whether the statin dose needs adjustment.; Patients using CYP3A-metabolized statins should have cholesterol levels monitored after Tracleer is initiated to see whether the statin dose needs adjustment.; When consideration of the potential benefits, and known and unknown risks leads to concomitant use, measure serum aminotransferases weekly for the first 4 weeks before reverting to normal monitoring.; 
RIFAMPICIN$Drug$DB01045$Dabigatran etexilate$Drug$DB06695$true$Decrease_Interaction$
RIFAMPICIN$Drug$DB01045$Digoxin$Drug$DB00390$true$Decrease_Interaction$
RIFAMPICIN$Drug$DB01045$DILTIAZEM$Drug$DB00343$true$Decrease_Interaction$Each tablet of CARDIZEM contains 30 mg, 60 mg, 90 mg, or 120 mg diltiazem hydrochloride.; Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. ; &lt;item&gt;Tiazac also contains: black iron oxide, D - C Red No. ; 
RIFAMPICIN$Drug$DB01045$Losartan$Drug$DB00678$true$Decrease_Interaction$Coadministration of losartan and cimetidine led to an increase of about 18% in AUC of losartan but did not affect the pharmacokinetics of its active metabolite. ; Potassium Supplements: A patient receiving losartan potassium and hydrochlorothiazide tablets should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician (see PRECAUTIONS, Drug Interactions, Losartan Potassium).; Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration. ; Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite. ; The patients should be told that if syncope occurs, losartan potassium and hydrochlorothiazide tablets should be discontinued until the physician has been consulted.; No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine, and phenobarbital. ; No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. ; Symptomatic Hypotension: A patient receiving losartan potassium and hydrochlorothiazide tablets should be cautioned that lightheadedness can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. ; 
RIFAMPICIN$Drug$DB01045$Treprostinil$Drug$DB00374$true$Decrease_Interaction$
Ritonavir$Drug$DB00503$RIVAROXABAN$Drug$DB06228$true$Increase_Interaction$In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; 
Ritonavir$Drug$DB00503$RIVAROXABAN$Drug$DB06228$true$Specific_Interaction$In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. ; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.; 
Salicyclic acid$Drug$DB00936$PHENYTOIN$Drug$DB00252$true$Decrease_Interaction$
Salicyclic acid$Drug$DB00936$Valproic Acid$Drug$DB00313$true$Increase_Interaction$
SALICYLIC ACID$Drug$DB00936$PHENYTOIN$Drug$DB00252$true$Decrease_Interaction$
SALICYLIC ACID$Drug$DB00936$Valproic Acid$Drug$DB00313$true$Increase_Interaction$
Sevelamer$Drug$DB00658$CIPROFLOXACIN$Drug$DB00537$true$Decrease_Interaction$
Sildenafil$Drug$DB00203$BOSENTAN$Drug$DB00559$true$Increase_Interaction$Clinical experience with concomitant administration of Tracleer and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among Tracleer- and placebo-treated patients.; Coadministration of bosentan 500 mg twice daily for 6 days in normal volunteers decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A substrate) by 29 and 38%, respectively. ; Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.; No dose adjustment of Tracleer is necessary, but increased effects of Tracleer should be considered.; 7.11 Digoxin, Nimodipine, and Losartan; Coadministration of bosentan 125 mg twice daily and ketoconazole, a potent CYP3A inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold in normal volunteers. ; In normal volunteers, coadministration of multiple doses of 125 mg twice daily bosentan and 80 mg three times daily sildenafil resulted in a reduction of sildenafil plasma concentrations by 63% and increased bosentan plasma concentrations by 50%. ; 
Sildenafil$Drug$DB00203$Ritonavir$Drug$DB00503$true$Caution_Interaction$&lt;item&gt;Use with organic nitrates (4); 
Sildenafil$Drug$DB00203$Sildenafil$Drug$DB00203$true$Caution_Interaction$
SIMVASTATIN$Drug$DB00641$AMIODARONE$Drug$DB01118$true$Caution_Interaction$Limit the dose of simvastatin in patients on amiodarone to 20 mg daily. ; Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as amiodarone may increase the plasma concentration of these drugs.; Cyclosporine (CYP3A substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.; This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes or are substrates for p-glycoprotein. ; Limit the daily dose of lovastatin to 40 mg. ; The use of HMG-CoA reductase inhibitors that are CYP3A4 substrates in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.; 
Simvastatin$Drug$DB00641$DILTIAZEM$Drug$DB00343$true$Caution_Interaction$In a healthy volunteer cross-over study (N 10), co-administration of a single 20 mg dose of simvastatin at the end of a 14 day regimen with 120 mg BID diltiazem SR resulted in a 5-fold increase in mean simvastatin AUC versus simvastatin alone. ; &lt;item&gt;Also contains: colloidal silicon dioxide, D - C Yellow #10 Aluminum Lake, FD - C Blue #1 Aluminum Lake (30 mg and 90 mg), FD - C Yellow #6 Aluminum Lake (60 mg and 120 mg), hydroxypropyl cellulose, hypromellose, lactose, magnesium stearate, methylparaben, microcrystalline cellulose, and polyethylene glycol.; In a ten-subject randomized, open label, 4-way cross-over study, co-administration of diltiazem (120 mg BID diltiazem SR for 2 weeks) with a single 20 mg dose of lovastatin resulted in 3- to 4-fold increase in mean lovastatin AUC and Cmax versus lovastatin alone. ; Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. ; Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.; If co-administration of simvastatin with diltiazem is required, limit the daily doses of simvastatin to 10 mg and diltiazem to 240 mg.; In the same study, there was no significant change in 20 mg single dose pravastatin AUC and Cmax during diltiazem coadministration. ; Subjects with increased average steady-state exposures of diltiazem showed a greater fold increase in simvastatin exposure. ; Computer-based simulations showed that at a daily dose of 480 mg of diltiazem, an 8- to 9-fold mean increase in simvastatin AUC can be expected. ; 
SIMVASTATIN$Drug$DB00641$Verapamil$Drug$DB00661$true$Caution_Interaction$Co-administration of multiple doses of 10 mg of verapamil with 80 mg simvastatin resulted in exposure to simvastatin 2.5-fold that following simvastatin alone. ; Limit the dose of simvastatin in patients on verapamil to 10 mg daily. ; If concomitant use of such agents is indicated, they should be used with caution and with appropriate monitoring of serum potassium (see PRECAUTIONS ).; In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including trandolapril, may result in deterioration of renal function, including possible acute renal failure. ; Trandolapril can attenuate potassium loss caused by thiazide diuretics and increase serum potassium when used alone. ; Limit the daily dose of lovastatin to 40 mg. ; The use of HMG-CoA reductase inhibitors that are CYP3A4 substrates in combination with verapamil has been associated with reports of myopathy/rhabdomyolysis.; Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ; No clinically significant pharmacokinetic interaction has been found between trandolapril (or its metabolites) and furosemide.; In a few reported cases, co-administration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as verapamil may increase the plasma concentration of these drugs.; Verapamil may increase blood alcohol concentrations and prolong its effects.; 
Sotalol$Drug$DB00489$Digoxin$Drug$DB00390$true$Specific_Interaction$Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. ; Concomitant use can increase the risk of bradycardia.; Proarrhythmic events were more common in sotalol treated patients also receiving digoxin; ; Additive Class II effects would also be anticipated with the use of other beta-blocking agents concomitantly with Betapace.; Proarrhythmic events were more common in Betapace treated patients also receiving digoxin, it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for proarrhythmia, in the patients receiving digoxin. ; Class Ia antiarrhythmic drugs, such as disopyramide, quinidine and procainamide and other Class III drugs (e.g., amiodarone) are not recommended as concomitant therapy with Betapace, because of their potential to prolong refractoriness (see WARNINGS ). ; Single and multiple doses of Betapace do not substantially affect serum digoxin levels. ; Betapace AF should be administered with caution in conjunction with calcium blocking drugs because of possible additive effects on atrioventricular conduction or ventricular function. ; 
Spironolactone$Drug$DB00421$Digoxin$Drug$DB00390$true$Increase_Interaction$Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.; Lithium: Lithium generally should not be given with diuretics. ; Pressor amines (e.g., norepinephrine): Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. ; Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant may result.; Combination of NSAIDs, e.g., indomethacin, with potassium-sparing diuretics has been associated with severe hyperkalemia. ; Nonsteroidal anti-inflammatory drugs (NSAIDs): In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics. ; Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with ALDACTAZIDE.; Therefore, when ALDACTAZIDE and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.; Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia, may occur.; Digoxin: Spironolactone has been shown to increase the half-life of digoxin. ; 
Spironolactone$Drug$DB00421$INDOMETHACIN$Drug$DB00328$true$Specific_Interaction$ALDACTONE (spironolactone) tablet, film coated; 
Spironolactone$Drug$DB00421$NOREPINEPHRINE$Drug$DB00368$true$Specific_Interaction$Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant may result.; Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia, may occur.; Digoxin: Spironolactone has been shown to increase the half-life of digoxin. ; Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with ALDACTAZIDE.; Therefore, when ALDACTAZIDE and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.; Combination of NSAIDs, e.g., indomethacin, with potassium-sparing diuretics has been associated with severe hyperkalemia. ; Lithium: Lithium generally should not be given with diuretics. ; Nonsteroidal anti-inflammatory drugs (NSAIDs): In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics. ; Pressor amines (e.g., norepinephrine): Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. ; Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.; 
Spironolactone$Drug$DB00421$Triamterene$Drug$DB00384$true$Specific_Interaction$Drug Label for drug brand Dyrenium, containing Triamterene.; 
Sulfasalazine$Drug$DB00795$Digoxin$Drug$DB00390$true$Decrease_Interaction$
TACROLIMUS$Drug$DB00864$Bosentan$Drug$DB00559$true$Caution_Interaction$Coadministration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals. ; The effect of Tracleer on rifampin levels has not been assessed. ; When consideration of the potential benefits, and known and unknown risks leads to concomitant use, measure serum aminotransferases weekly for the first 4 weeks before reverting to normal monitoring.; Coadministration of bosentan and rifampin in normal volunteers resulted in a mean 6-fold increase in bosentan trough levels after the first concomitant dose (likely due to inhibition of OATP by rifampin), but about a 60% decrease in bosentan levels at steady-state. ; Coadministration of tacrolimus and Tracleer has not been studied in humans. ; Caution should be exercised if tacrolimus and Tracleer are used together.; Patients using CYP3A-metabolized statins should have cholesterol levels monitored after Tracleer is initiated to see whether the statin dose needs adjustment.; Coadministration of bosentan and rifampin in normal volunteers resulted in a mean 6-fold increase in bosentan trough levels after the first concomitant dose (likely due to inhibition of OATP by rifampin), but about a 60% decrease in bosentan levels at steady-state. ; Coadministration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals. ; Caution should be exercised if tacrolimus and Tracleer are used together.; Patients using CYP3A-metabolized statins should have cholesterol levels monitored after Tracleer is initiated to see whether the statin dose needs adjustment.; When consideration of the potential benefits, and known and unknown risks leads to concomitant use, measure serum aminotransferases weekly for the first 4 weeks before reverting to normal monitoring.; Coadministration of tacrolimus and Tracleer has not been studied in humans. ; The effect of Tracleer on rifampin levels has not been assessed. ; 
TACROLIMUS$Drug$DB00864$BOSENTAN$Drug$DB00559$true$Increase_Interaction$Coadministration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals. ; The effect of Tracleer on rifampin levels has not been assessed. ; When consideration of the potential benefits, and known and unknown risks leads to concomitant use, measure serum aminotransferases weekly for the first 4 weeks before reverting to normal monitoring.; Coadministration of bosentan and rifampin in normal volunteers resulted in a mean 6-fold increase in bosentan trough levels after the first concomitant dose (likely due to inhibition of OATP by rifampin), but about a 60% decrease in bosentan levels at steady-state. ; Coadministration of tacrolimus and Tracleer has not been studied in humans. ; Caution should be exercised if tacrolimus and Tracleer are used together.; Patients using CYP3A-metabolized statins should have cholesterol levels monitored after Tracleer is initiated to see whether the statin dose needs adjustment.; Coadministration of bosentan and rifampin in normal volunteers resulted in a mean 6-fold increase in bosentan trough levels after the first concomitant dose (likely due to inhibition of OATP by rifampin), but about a 60% decrease in bosentan levels at steady-state. ; Coadministration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals. ; Caution should be exercised if tacrolimus and Tracleer are used together.; Patients using CYP3A-metabolized statins should have cholesterol levels monitored after Tracleer is initiated to see whether the statin dose needs adjustment.; When consideration of the potential benefits, and known and unknown risks leads to concomitant use, measure serum aminotransferases weekly for the first 4 weeks before reverting to normal monitoring.; Coadministration of tacrolimus and Tracleer has not been studied in humans. ; The effect of Tracleer on rifampin levels has not been assessed. ; 
TAK-390MR$Drug$DB05351$Clopidogrel$Drug$DB00758$true$Specific_Interaction$
Telaprevir$Drug$DB05521$ATORVASTATIN$Drug$DB01076$true$Caution_Interaction$
TELITHROMYCIN$Drug$DB00976$Verapamil$Drug$DB00661$true$Increase_Interaction$&lt;main&gt;Trandolapril is the ethyl ester prodrug of a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, trandolaprilat. ; Therapy with rifampin may markedly reduce oral verapamil bioavailability. ; Verapamil may increase carbamazepine concentrations during combined therapy. ; The antihypertensive effect of ACE inhibitors, including trandolapril may be attenuated by NSAIDs.; Phenobarbital therapy may increase verapamil clearance.; There have been reports that erythromycin and telithromycin may increase concentrations of verapamil.; Monitor renal function periodically in patients receiving trandolapril and NSAID therapy.; 
TELMISARTAN$Drug$DB00966$Digoxin$Drug$DB00390$true$Increase_Interaction$Because lithium should not be used with diuretics, the use of lithium with telmisartan and hydrochlorothiazide is not recommended.; It is, therefore, recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing telmisartan to avoid possible over- or under-digitalization.; Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) : In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible acute renal failure. ; Digoxin : When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. ; Monitor renal function periodically in patients receiving telmisartan and NSAID therapy.; Lithium : Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. ; The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.; Cases have also been reported with angiotensin II receptor antagonists including telmisartan. ; Avoid use of aliskiren with MICARDIS HCT in patients with renal impairment (GFR 60 mL/min).; 
TELMISARTAN$Drug$DB00966$Ramipril$Drug$DB00178$true$Caution_Interaction$In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. ; Other ACE inhibitors have had less than additive effects with beta adrenergic blockers, presumably because both drug classes lower blood pressure by inhibiting parts of the renin-angiotensin-aldosterone system.; Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. ; &lt;item&gt;Alcohol, barbiturates, or narcotics : Potentiation of orthostatic hypotension may occur.; In contrast, Cmax and AUC of telmisartan decrease by 31% and 16%, respectively. ; Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.; When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.; Therefore, concomitant use of telmisartan and ramipril is not recommended see Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7).; &lt;item&gt;Alcohol, barbiturates, or narcotics : Potentiation of orthostatic hypotension may occur.; Other ACE inhibitors have had less than additive effects with beta adrenergic blockers, presumably because both drug classes lower blood pressure by inhibiting parts of the renin-angiotensin-aldosterone system.; Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes (see PRECAUTIONS, Drug Interactions ).; When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.; ALTACE is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor).; In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. ; Limited experience in controlled and uncontrolled trials combining ALTACE with a calcium channel blocker, a loop diuretic, or triple therapy (beta-blocker, vasodilator, and a diuretic) indicate no unusual drug-drug interactions. ; Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. ; ALTACE is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor).; Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium, therefore, frequent monitoring of serum lithium levels is recommended. ; Other Drugs : Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide or ibuprofen. ; Therefore, concomitant use of telmisartan and ramipril is not recommended see Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7).; The combination of ramipril and propranolol showed no adverse effects on dynamic parameters (blood pressure and heart rate).; Ramipril and Ramiprilat : Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. ; Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes (see PRECAUTIONS, Drug Interactions ).; Ramipril and Ramiprilat : Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. ; &lt;item&gt;Antidiabetic drugs (oral agents and insulin) : Dosage adjustment of the antidiabetic drug may be required.; Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium, therefore, frequent monitoring of serum lithium levels is recommended. ; Warfarin : Telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration, this decrease did not result in a change in International Normalized Ratio (INR).; Limited experience in controlled and uncontrolled trials combining ALTACE with a calcium channel blocker, a loop diuretic, or triple therapy (beta-blocker, vasodilator, and a diuretic) indicate no unusual drug-drug interactions. ; &lt;item&gt;Antidiabetic drugs (oral agents and insulin) : Dosage adjustment of the antidiabetic drug may be required.; Warfarin : Telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration, this decrease did not result in a change in International Normalized Ratio (INR).; The combination of ramipril and propranolol showed no adverse effects on dynamic parameters (blood pressure and heart rate).; Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.; In contrast, Cmax and AUC of telmisartan decrease by 31% and 16%, respectively. ; Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes (see PRECAUTIONS, Drug Interactions ).; Other Drugs : Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide or ibuprofen. ; 
Telmisartan$Drug$DB00966$Ramipril$Drug$DB00178$true$Increase_Interaction$In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. ; Other ACE inhibitors have had less than additive effects with beta adrenergic blockers, presumably because both drug classes lower blood pressure by inhibiting parts of the renin-angiotensin-aldosterone system.; Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. ; &lt;item&gt;Alcohol, barbiturates, or narcotics : Potentiation of orthostatic hypotension may occur.; In contrast, Cmax and AUC of telmisartan decrease by 31% and 16%, respectively. ; Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.; When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.; Therefore, concomitant use of telmisartan and ramipril is not recommended see Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7).; &lt;item&gt;Alcohol, barbiturates, or narcotics : Potentiation of orthostatic hypotension may occur.; Other ACE inhibitors have had less than additive effects with beta adrenergic blockers, presumably because both drug classes lower blood pressure by inhibiting parts of the renin-angiotensin-aldosterone system.; Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes (see PRECAUTIONS, Drug Interactions ).; When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.; ALTACE is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor).; In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. ; Limited experience in controlled and uncontrolled trials combining ALTACE with a calcium channel blocker, a loop diuretic, or triple therapy (beta-blocker, vasodilator, and a diuretic) indicate no unusual drug-drug interactions. ; Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. ; ALTACE is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor).; Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium, therefore, frequent monitoring of serum lithium levels is recommended. ; Other Drugs : Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide or ibuprofen. ; Therefore, concomitant use of telmisartan and ramipril is not recommended see Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7).; The combination of ramipril and propranolol showed no adverse effects on dynamic parameters (blood pressure and heart rate).; Ramipril and Ramiprilat : Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. ; Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes (see PRECAUTIONS, Drug Interactions ).; Ramipril and Ramiprilat : Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. ; &lt;item&gt;Antidiabetic drugs (oral agents and insulin) : Dosage adjustment of the antidiabetic drug may be required.; Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium, therefore, frequent monitoring of serum lithium levels is recommended. ; Warfarin : Telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration, this decrease did not result in a change in International Normalized Ratio (INR).; Limited experience in controlled and uncontrolled trials combining ALTACE with a calcium channel blocker, a loop diuretic, or triple therapy (beta-blocker, vasodilator, and a diuretic) indicate no unusual drug-drug interactions. ; &lt;item&gt;Antidiabetic drugs (oral agents and insulin) : Dosage adjustment of the antidiabetic drug may be required.; Warfarin : Telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration, this decrease did not result in a change in International Normalized Ratio (INR).; The combination of ramipril and propranolol showed no adverse effects on dynamic parameters (blood pressure and heart rate).; Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.; In contrast, Cmax and AUC of telmisartan decrease by 31% and 16%, respectively. ; Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes (see PRECAUTIONS, Drug Interactions ).; Other Drugs : Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide or ibuprofen. ; 
TELMISARTAN$Drug$DB00966$Ramipril$Drug$DB00178$true$Specific_Interaction$In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. ; Other ACE inhibitors have had less than additive effects with beta adrenergic blockers, presumably because both drug classes lower blood pressure by inhibiting parts of the renin-angiotensin-aldosterone system.; Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. ; &lt;item&gt;Alcohol, barbiturates, or narcotics : Potentiation of orthostatic hypotension may occur.; In contrast, Cmax and AUC of telmisartan decrease by 31% and 16%, respectively. ; Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.; When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.; Therefore, concomitant use of telmisartan and ramipril is not recommended see Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7).; &lt;item&gt;Alcohol, barbiturates, or narcotics : Potentiation of orthostatic hypotension may occur.; Other ACE inhibitors have had less than additive effects with beta adrenergic blockers, presumably because both drug classes lower blood pressure by inhibiting parts of the renin-angiotensin-aldosterone system.; Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes (see PRECAUTIONS, Drug Interactions ).; When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.; ALTACE is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor).; In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. ; Limited experience in controlled and uncontrolled trials combining ALTACE with a calcium channel blocker, a loop diuretic, or triple therapy (beta-blocker, vasodilator, and a diuretic) indicate no unusual drug-drug interactions. ; Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. ; ALTACE is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor).; Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium, therefore, frequent monitoring of serum lithium levels is recommended. ; Other Drugs : Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide or ibuprofen. ; Therefore, concomitant use of telmisartan and ramipril is not recommended see Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7).; The combination of ramipril and propranolol showed no adverse effects on dynamic parameters (blood pressure and heart rate).; Ramipril and Ramiprilat : Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. ; Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes (see PRECAUTIONS, Drug Interactions ).; Ramipril and Ramiprilat : Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. ; &lt;item&gt;Antidiabetic drugs (oral agents and insulin) : Dosage adjustment of the antidiabetic drug may be required.; Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium, therefore, frequent monitoring of serum lithium levels is recommended. ; Warfarin : Telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration, this decrease did not result in a change in International Normalized Ratio (INR).; Limited experience in controlled and uncontrolled trials combining ALTACE with a calcium channel blocker, a loop diuretic, or triple therapy (beta-blocker, vasodilator, and a diuretic) indicate no unusual drug-drug interactions. ; &lt;item&gt;Antidiabetic drugs (oral agents and insulin) : Dosage adjustment of the antidiabetic drug may be required.; Warfarin : Telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration, this decrease did not result in a change in International Normalized Ratio (INR).; The combination of ramipril and propranolol showed no adverse effects on dynamic parameters (blood pressure and heart rate).; Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.; In contrast, Cmax and AUC of telmisartan decrease by 31% and 16%, respectively. ; Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes (see PRECAUTIONS, Drug Interactions ).; Other Drugs : Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide or ibuprofen. ; 
TETRACYCLINE$Drug$DB00759$Digoxin$Drug$DB00390$true$Increase_Interaction$
Tirofiban$Drug$DB00775$ACETYLSALICYLIC ACID$Drug$DB00945$true$Specific_Interaction$
Tolvaptan$Drug$DB06212$Digoxin$Drug$DB00390$true$Increase_Interaction$Co-administration of lovastatin, digoxin, furosemide, and hydrochlorothiazide with SAMSCA has no clinically relevant impact on the exposure to tolvaptan.; Co-administration of rifampin and SAMSCA reduces exposure to tolvaptan by 85%. ; The dose of SAMSCA may have to be increased Dosage and Administration (2.3) and Warnings and Precautions (5.5).; Lovastatin, Digoxin, Furosemide, and Hydrochlorothiazide; Co-administration of SAMSCA with digoxin increased digoxin AUC by 20% and Cmax by 30%.; Therefore, the expected clinical effects of SAMSCA in the presence of rifampin and other inducers (e.g., rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine and St. John's Wort) may not be observed at the usual dose levels of SAMSCA. ; 
Tolvaptan$Drug$DB06212$Lovastatin$Drug$DB00227$true$Increase_Interaction$Concomitant administration of tolvaptan with furosemide or hydrochlorothiazide results in a 24 hour urine volume/excretion rate that is similar to the rate after tolvaptan administration alone.; Although specific interaction studies were not performed, in clinical studies tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. ; Co-administration of lovastatin and SAMSCA increases the exposure to lovastatin and its active metabolite lovastatin- hydroxyacid by factors of 1.4 and 1.3, respectively. ; Co-administration of tolvaptan does not appear to alter the pharmacokinetics of warfarin, furosemide, hydrochlorothiazide, or amiodarone (or its active metabolite, desethylamiodarone) to a clinically significant degree.; Tolvaptan produces a greater 24 hour urine volume/excretion rate than does furosemide or hydrochlorothiazide. ; Warfarin, Amiodarone, Furosemide, and Hydrochlorothiazide; 
Tolvaptan$Drug$DB06212$RIFAMPICIN$Drug$DB01045$true$Specific_Interaction$Co-administration of SAMSCA with digoxin increased digoxin AUC by 20% and Cmax by 30%.; Lovastatin, Digoxin, Furosemide, and Hydrochlorothiazide; Therefore, the expected clinical effects of SAMSCA in the presence of rifampin and other inducers (e.g., rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine and St. John's Wort) may not be observed at the usual dose levels of SAMSCA. ; Co-administration of lovastatin, digoxin, furosemide, and hydrochlorothiazide with SAMSCA has no clinically relevant impact on the exposure to tolvaptan.; The dose of SAMSCA may have to be increased Dosage and Administration (2.3) and Warnings and Precautions (5.5).; Co-administration of rifampin and SAMSCA reduces exposure to tolvaptan by 85%. ; 
Torasemide$Drug$DB00214$INDOMETHACIN$Drug$DB00328$true$Specific_Interaction$
Torasemide$Drug$DB00214$Spironolactone$Drug$DB00421$true$Increase_Interaction$
Trazodone$Drug$DB00656$AMIODARONE$Drug$DB01118$true$Specific_Interaction$Cimetidine inhibits CYP3A and can increase serum amiodarone levels.; Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone. ; QT interval prolongation and TdP have been reported with the co-administration of loratadine and amiodarone.; QT interval prolongation and TdP have been reported with the co-administration of trazodone and amiodarone.; Trazodone, an antidepressant, is metabolized primarily by CYP3A. ; Do not take grapefruit juice during treatment with amiodarone.; 
TRIAMTERENE$Drug$DB00384$Chlorpropamide$Drug$DB00672$true$Specific_Interaction$Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including Dyrenium. ; 
Triamterene$Drug$DB00384$QUINIDINE$Drug$DB00908$true$Specific_Interaction$
TRIAZOLAM$Drug$DB00897$DILTIAZEM$Drug$DB00343$true$Increase_Interaction$
TRIMETHOPRIM$Drug$DB00440$Dofetilide$Drug$DB00204$true$Caution_Interaction$
TRIMETHOPRIM$Drug$DB00440$Dofetilide$Drug$DB00204$true$Specific_Interaction$
Verapamil$Drug$DB00661$ACETYLSALICYLIC ACID$Drug$DB00945$true$Specific_Interaction$Concomitant administration of R verapamil can decrease the clearance of paclitaxel.; In a few reported cases, co-administration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Aspirin: In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; There has been a report of increased quinidine levels during verapamil therapy.; Co-administration of multiple doses of 10 mg of verapamil with 80 mg simvastatin resulted in exposure to simvastatin 2.5-fold that following simvastatin alone. ; Limit the dose of simvastatin in patients on verapamil to 10 mg daily. ; Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as verapamil may increase the plasma concentration of these drugs.; In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; Limit the daily dose of lovastatin to 40 mg. ; The use of HMG-CoA reductase inhibitors that are CYP3A4 substrates in combination with verapamil has been associated with reports of myopathy/rhabdomyolysis.; Verapamil may increase blood alcohol concentrations and prolong its effects.; Verapamil significantly counteracted the effects of quinidine on AV conduction. ; Alcohol: Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol. ; Cimetidine: The interaction between cimetidine and chronically administered verapamil has not been studied. ; Grapefruit Juice: Grapefruit juice may significantly increase concentrations of verapamil. ; Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.; 
Verapamil$Drug$DB00661$Adenosine$Drug$DB00640$true$Specific_Interaction$
Verapamil$Drug$DB00661$Almotriptan$Drug$DB00918$true$Increase_Interaction$Concentrations of doxorubicin may be increased by the administration of verapamil.; Concentrations of verapamil may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or St John s Wort.; Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.; Verapamil therapy may increase serum levels of cyclosporin, sirolimus and tacrolimus.; Verapamil therapy may inhibit the clearance and increase the plasma levels of theophylline.; Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; There have been reports that verapamil may elevate the concentrations of the oral anti-diabetic glyburide.; When verapamil and colchicine are administered together, the potential inhibition of P-gp and/or CYP3A by verapamil may lead to increased exposure to colchicine (see PRECAUTIONS - Drug Interactions ).; 
Verapamil$Drug$DB00661$Buspirone$Drug$DB00490$true$Increase_Interaction$There have been reports that verapamil may elevate the concentrations of the oral anti-diabetic glyburide.; Verapamil therapy may increase serum levels of cyclosporin, sirolimus and tacrolimus.; Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; Concentrations of doxorubicin may be increased by the administration of verapamil.; Concentrations of verapamil may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or St John s Wort.; When verapamil and colchicine are administered together, the potential inhibition of P-gp and/or CYP3A by verapamil may lead to increased exposure to colchicine (see PRECAUTIONS - Drug Interactions ).; Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.; Verapamil therapy may inhibit the clearance and increase the plasma levels of theophylline.; 
Verapamil$Drug$DB00661$CARBAMAZEPINE$Drug$DB00564$true$Increase_Interaction$Cyclosporine: Verapamil therapy may increase serum levels of cyclosporine.; Inhalation Anesthetics: Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, should be titrated carefully to avoid excessive cardiovascular depression.; Carbamazepine: Verapamil therapy may increase carbamazepine concentrations during combined therapy. ; However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium. ; Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels. ; The antihypertensive effect of ACE inhibitors, including trandolapril may be attenuated by NSAIDs.; lithium levels have been observed sometimes to increase, sometimes to decrease, and sometimes to be unchanged. ; There have been reports that erythromycin and telithromycin may increase concentrations of verapamil.; This may produce carbamazepine side effects such as diplopia, headache, ataxia, or dizziness.; Phenobarbital therapy may increase verapamil clearance.; Verapamil may increase carbamazepine concentrations during combined therapy. ; &lt;main&gt;Trandolapril is the ethyl ester prodrug of a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, trandolaprilat. ; Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy; ; Monitor renal function periodically in patients receiving trandolapril and NSAID therapy.; Verapamil therapy may increase carbamazepine concentrations during combined therapy. ; clearance of verapamil was either reduced or unchanged.; Patients receiving both drugs must be monitored carefully.; Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.; Neuromuscular Blocking Agents: Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). ; Therapy with rifampin may markedly reduce oral verapamil bioavailability. ; Verapamil therapy may increase serum levels of cyclosporine.; Phenobarbital: Phenobarbital therapy may increase verapamil clearance.; Rifampin: Therapy with rifampin may markedly reduce oral verapamil bioavailability.; 
Verapamil$Drug$DB00661$Clonidine$Drug$DB00575$true$Caution_Interaction$Biochemical evidence points to separate binding sites for 1,4-dihydropyridines, phenylalkylamines, and the benzothiazepines (all located on the alpha-1 subunit). ; Monitor heart rate in patients receiving concomitant verapamil and clonidine.; Verapamil should be avoided in patients with severe left ventricular dysfunction (eg, ejection fraction less than 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker (see PRECAUTIONS, Drug interactions). ; The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. ; Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.; Verapamil can increase doxorubicin levels. ; Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). ; Hypotension and bradyarrhythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.; Hypotension and bradyarrhythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class.; It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.; Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. ; 
Verapamil$Drug$DB00661$COLCHICINE$Drug$DB01394$true$Increase_Interaction$Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.; There have been reports that verapamil may elevate the concentrations of the oral anti-diabetic glyburide.; Verapamil therapy may increase serum levels of cyclosporin, sirolimus and tacrolimus.; Concentrations of doxorubicin may be increased by the administration of verapamil.; When verapamil and colchicine are administered together, the potential inhibition of P-gp and/or CYP3A by verapamil may lead to increased exposure to colchicine (see PRECAUTIONS - Drug Interactions ).; Concentrations of verapamil may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or St John s Wort.; Verapamil therapy may inhibit the clearance and increase the plasma levels of theophylline.; Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; 
Verapamil$Drug$DB00661$CYCLOSPORINE$Drug$DB00091$true$Increase_Interaction$Carbamazepine: Verapamil therapy may increase carbamazepine concentrations during combined therapy. ; Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). ; Rifampin: Therapy with rifampin may markedly reduce oral verapamil bioavailability.; This may produce carbamazepine side effects such as diplopia, headache, ataxia, or dizziness.; Cyclosporine: Verapamil therapy may increase serum levels of cyclosporine.; It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.; Verapamil may inhibit the clearance and increase the plasma levels of theophylline.; When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, should be titrated carefully to avoid excessive cardiovascular depression.; When used concomitantly, inhalation anesthetics and calcium channel blocking agents, such as verapamil, should each be titrated carefully to avoid excessive cardiovascular depression.; Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels. ; Inhalation Anesthetics: Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; Patients receiving both drugs must be monitored carefully.; Phenobarbital therapy may increase verapamil clearance.; Phenobarbital: Phenobarbital therapy may increase verapamil clearance.; Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; Neuromuscular Blocking Agents: Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). ; However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium. ; When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, should each be titrated carefully to avoid excessive cardiovascular depression.; Verapamil therapy may increase carbamazepine concentrations during combined therapy. ; Verapamil therapy may increase serum levels of cyclosporine.; 
Verapamil$Drug$DB00661$Dabigatran etexilate$Drug$DB06695$true$Increase_Interaction$
Verapamil$Drug$DB00661$Digitoxin$Drug$DB01396$true$Increase_Interaction$Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. ; Patients receiving these combinations should be appropriately monitored. ; Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure. ; In patients with hepatic cirrhosis, the influence of verapamil on digoxin kinetics is magnified. ; Maintenance and digitalization doses should be reduced when verapamil is administered, and the patient should be reassessed to avoid over- to under-digitalization. ; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in a reduction in blood pressure that is excessive in some patients. ; In previous clinical trials with other verapamil formulations related to the control of ventricular response in digitalized patients who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.; 
Verapamil$Drug$DB00661$Digoxin$Drug$DB00390$true$Increase_Interaction$A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil. ; Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.; Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.; Maintenance and digitalization doses should be reduced when verapamil is administered, and the patient should be reassessed to avoid over- to under-digitalization. ; Clinical use of verapamil in digitalized patients has shown the combination to be well tolerated if digoxin doses are properly adjusted. ; The combination of sustained-release verapamil and beta-adrenergic blocking agents has not been studied. ; A variable effect has been seen when verapamil and atenolol were given together.; In patients with hepatic cirrhosis, the influence of verapamil on digoxin kinetics is magnified. ; Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure. ; However, chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. ; The combination should be used only with caution and close monitoring.; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in a reduction in blood pressure that is excessive in some patients. ; Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. ; However, there have been reports of excessive bradycardia and AV block, including complete heart block, when the combination has been used for the treatment of hypertension. ; In previous clinical trials with other verapamil formulations related to the control of ventricular response in digitalized patients who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.; Patients receiving these combinations should be appropriately monitored. ; 
Verapamil$Drug$DB00661$Digoxin$Drug$DB00390$true$Specific_Interaction$A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil. ; Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.; Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.; Maintenance and digitalization doses should be reduced when verapamil is administered, and the patient should be reassessed to avoid over- to under-digitalization. ; Clinical use of verapamil in digitalized patients has shown the combination to be well tolerated if digoxin doses are properly adjusted. ; The combination of sustained-release verapamil and beta-adrenergic blocking agents has not been studied. ; A variable effect has been seen when verapamil and atenolol were given together.; In patients with hepatic cirrhosis, the influence of verapamil on digoxin kinetics is magnified. ; Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure. ; However, chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. ; The combination should be used only with caution and close monitoring.; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in a reduction in blood pressure that is excessive in some patients. ; Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. ; However, there have been reports of excessive bradycardia and AV block, including complete heart block, when the combination has been used for the treatment of hypertension. ; In previous clinical trials with other verapamil formulations related to the control of ventricular response in digitalized patients who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.; Patients receiving these combinations should be appropriately monitored. ; 
Verapamil$Drug$DB00661$Dofetilide$Drug$DB00204$true$Increase_Interaction$TIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. ; TIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. ; 
Verapamil$Drug$DB00661$Dofetilide$Drug$DB00204$true$Specific_Interaction$TIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. ; TIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. ; 
Verapamil$Drug$DB00661$DOXORUBICIN$Drug$DB00997$true$Increase_Interaction$Verapamil can increase doxorubicin levels. ; Monitor heart rate in patients receiving concomitant verapamil and clonidine.; Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. ; Hypotension and bradyarrhythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.; Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.; The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. ; 
Verapamil$Drug$DB00661$Dronedarone$Drug$DB04855$true$Increase_Interaction$
Verapamil$Drug$DB00661$ETHANOL$Substance$DB00898$true$Increase_Interaction$Verapamil may increase blood alcohol concentrations and prolong its effects.; Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.; Aspirin: In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Co-administration of multiple doses of 10 mg of verapamil with 80 mg simvastatin resulted in exposure to simvastatin 2.5-fold that following simvastatin alone. ; clearance of verapamil was either reduced or unchanged.; Hypotension and bradyarrhythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.; There has been a report of increased quinidine levels during verapamil therapy.; Alcohol: Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol. ; Aspirin: In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Alcohol: Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol. ; Verapamil can increase doxorubicin levels. ; Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.; The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. ; In a few reported cases, co-administration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as verapamil may increase the plasma concentration of these drugs.; The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. ; Verapamil has been found to inhibit ethanol elimination significantly, resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol (see CLINICAL PHARMACOLOGY, Pharmacokinetics and metabolism).; Cimetidine: The interaction between cimetidine and chronically administered verapamil has not been studied. ; Monitor heart rate in patients receiving concomitant verapamil and clonidine.; Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. ; There has been a report of increased quinidine levels during verapamil therapy.; Grapefruit Juice: Grapefruit juice may significantly increase concentrations of verapamil. ; Limit the dose of simvastatin in patients on verapamil to 10 mg daily. ; Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. ; The interaction between cimetidine and chronically administered verapamil has not been studied. ; Hypotension and bradyarrhythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.; Limit the daily dose of lovastatin to 40 mg. ; The use of HMG-CoA reductase inhibitors that are CYP3A4 substrates in combination with verapamil has been associated with reports of myopathy/rhabdomyolysis.; Monitor heart rate in patients receiving concomitant verapamil and clonidine.; Cimetidine: The interaction between cimetidine and chronically administered verapamil has not been studied. ; Grapefruit Juice: Grapefruit juice may significantly increase concentrations of verapamil. ; Verapamil can increase doxorubicin levels. ; 
Verapamil$Drug$DB00661$ETHANOL$Substance$DB00898$true$Specific_Interaction$Verapamil may increase blood alcohol concentrations and prolong its effects.; Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.; Aspirin: In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Co-administration of multiple doses of 10 mg of verapamil with 80 mg simvastatin resulted in exposure to simvastatin 2.5-fold that following simvastatin alone. ; clearance of verapamil was either reduced or unchanged.; Hypotension and bradyarrhythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.; There has been a report of increased quinidine levels during verapamil therapy.; Alcohol: Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol. ; Aspirin: In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Alcohol: Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol. ; Verapamil can increase doxorubicin levels. ; Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.; The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. ; In a few reported cases, co-administration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as verapamil may increase the plasma concentration of these drugs.; The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. ; Verapamil has been found to inhibit ethanol elimination significantly, resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol (see CLINICAL PHARMACOLOGY, Pharmacokinetics and metabolism).; Cimetidine: The interaction between cimetidine and chronically administered verapamil has not been studied. ; Monitor heart rate in patients receiving concomitant verapamil and clonidine.; Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. ; There has been a report of increased quinidine levels during verapamil therapy.; Grapefruit Juice: Grapefruit juice may significantly increase concentrations of verapamil. ; Limit the dose of simvastatin in patients on verapamil to 10 mg daily. ; Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. ; The interaction between cimetidine and chronically administered verapamil has not been studied. ; Hypotension and bradyarrhythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.; Limit the daily dose of lovastatin to 40 mg. ; The use of HMG-CoA reductase inhibitors that are CYP3A4 substrates in combination with verapamil has been associated with reports of myopathy/rhabdomyolysis.; Monitor heart rate in patients receiving concomitant verapamil and clonidine.; Cimetidine: The interaction between cimetidine and chronically administered verapamil has not been studied. ; Grapefruit Juice: Grapefruit juice may significantly increase concentrations of verapamil. ; Verapamil can increase doxorubicin levels. ; 
Verapamil$Drug$DB00661$Flecainide$Drug$DB01195$true$Caution_Interaction$
Verapamil$Drug$DB00661$IMIPRAMINE$Drug$DB00458$true$Increase_Interaction$Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; Concentrations of verapamil may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or St John s Wort.; There have been reports that verapamil may elevate the concentrations of the oral anti-diabetic glyburide.; Verapamil therapy may inhibit the clearance and increase the plasma levels of theophylline.; Verapamil therapy may increase serum levels of cyclosporin, sirolimus and tacrolimus.; When verapamil and colchicine are administered together, the potential inhibition of P-gp and/or CYP3A by verapamil may lead to increased exposure to colchicine (see PRECAUTIONS - Drug Interactions ).; Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.; Concentrations of doxorubicin may be increased by the administration of verapamil.; 
Verapamil$Drug$DB00661$LITHIUM$Drug$DB01356$true$Increase_Interaction$
Verapamil$Drug$DB00661$LITHIUM$Drug$DB01356$true$Specific_Interaction$
Verapamil$Drug$DB00661$MIDAZOLAM$Drug$DB00683$true$Increase_Interaction$Concentrations of doxorubicin may be increased by the administration of verapamil.; When verapamil and colchicine are administered together, the potential inhibition of P-gp and/or CYP3A by verapamil may lead to increased exposure to colchicine (see PRECAUTIONS - Drug Interactions ).; There have been reports that verapamil may elevate the concentrations of the oral anti-diabetic glyburide.; Verapamil therapy may increase serum levels of cyclosporin, sirolimus and tacrolimus.; Verapamil therapy may inhibit the clearance and increase the plasma levels of theophylline.; Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.; Concentrations of verapamil may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or St John s Wort.; 
Verapamil$Drug$DB00661$Paclitaxel$Drug$DB01229$true$Increase_Interaction$In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension. ; Concomitant administration of R verapamil can decrease the clearance of paclitaxel.; In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.; There has been a report of increased quinidine levels during verapamil therapy.; The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; Verapamil significantly counteracted the effects of quinidine on AV conduction. ; 
Verapamil$Drug$DB00661$Prazosin$Drug$DB00457$true$Increase_Interaction$In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; Patients receiving these combinations should be appropriately monitored. ; Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure. ; Verapamil significantly counteracted the effects of quinidine on AV conduction. ; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in a reduction in blood pressure that is excessive in some patients. ; Monitor patients receiving these combinations appropriately. ; Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.; Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.; Disopyramide: Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers) will usually have an additive effect on lowering blood pressure. ; A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients. ; Flecainide: A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; Quinidine: In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.. ; Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; 
Verapamil$Drug$DB00661$Prazosin$Drug$DB00457$true$Specific_Interaction$In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; Patients receiving these combinations should be appropriately monitored. ; Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure. ; Verapamil significantly counteracted the effects of quinidine on AV conduction. ; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in a reduction in blood pressure that is excessive in some patients. ; Monitor patients receiving these combinations appropriately. ; Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.; Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.; Disopyramide: Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers) will usually have an additive effect on lowering blood pressure. ; A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients. ; Flecainide: A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; Quinidine: In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.. ; Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; 
Verapamil$Drug$DB00661$QUINIDINE$Drug$DB00908$true$Caution_Interaction$Disopyramide: Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.. ; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients. ; Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.; A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiologic effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; The interaction between cimetidine and chronically administered verapamil has not been studied. ; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.; A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.; In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension. ; Quinidine: In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.; There has been a report of increased quinidine levels during verapamil therapy.; Disopyramide: Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; Flecainide: A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.. ; Verapamil significantly counteracted the effects of quinidine on AV conduction. ; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients. ; Flecainide: A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.; In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension. ; Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; Verapamil significantly counteracted the effects of quinidine on AV conduction. ; Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.; Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.; Quinidine: In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiologic effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; There has been a report of increased quinidine levels during verapamil therapy.; Concomitant administration of R verapamil can decrease the clearance of paclitaxel.; Concomitant administration of R verapamil can decrease the clearance of paclitaxel.; In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; 
Verapamil$Drug$DB00661$QUINIDINE$Drug$DB00908$true$Specific_Interaction$Disopyramide: Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.. ; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients. ; Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.; A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiologic effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; The interaction between cimetidine and chronically administered verapamil has not been studied. ; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.; A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.; In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension. ; Quinidine: In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.; There has been a report of increased quinidine levels during verapamil therapy.; Disopyramide: Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; Flecainide: A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.. ; Verapamil significantly counteracted the effects of quinidine on AV conduction. ; Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients. ; Flecainide: A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ; In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.; Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.; In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension. ; Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.; Verapamil significantly counteracted the effects of quinidine on AV conduction. ; Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.; Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.; Quinidine: In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ; The electrophysiologic effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; There has been a report of increased quinidine levels during verapamil therapy.; Concomitant administration of R verapamil can decrease the clearance of paclitaxel.; Concomitant administration of R verapamil can decrease the clearance of paclitaxel.; In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. ; 
Verapamil$Drug$DB00661$SIMVASTATIN$Drug$DB00641$true$Caution_Interaction$Limit the daily dose of lovastatin to 40 mg. ; Verapamil may increase blood alcohol concentrations and prolong its effects.; Trandolapril can attenuate potassium loss caused by thiazide diuretics and increase serum potassium when used alone. ; In a few reported cases, co-administration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; The use of HMG-CoA reductase inhibitors that are CYP3A4 substrates in combination with verapamil has been associated with reports of myopathy/rhabdomyolysis.; In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including trandolapril, may result in deterioration of renal function, including possible acute renal failure. ; No clinically significant pharmacokinetic interaction has been found between trandolapril (or its metabolites) and furosemide.; Co-administration of multiple doses of 10 mg of verapamil with 80 mg simvastatin resulted in exposure to simvastatin 2.5-fold that following simvastatin alone. ; If concomitant use of such agents is indicated, they should be used with caution and with appropriate monitoring of serum potassium (see PRECAUTIONS ).; Limit the dose of simvastatin in patients on verapamil to 10 mg daily. ; Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as verapamil may increase the plasma concentration of these drugs.; Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ; 
Verapamil$Drug$DB00661$SIMVASTATIN$Drug$DB00641$true$Increase_Interaction$Limit the daily dose of lovastatin to 40 mg. ; Verapamil may increase blood alcohol concentrations and prolong its effects.; Trandolapril can attenuate potassium loss caused by thiazide diuretics and increase serum potassium when used alone. ; In a few reported cases, co-administration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.; The use of HMG-CoA reductase inhibitors that are CYP3A4 substrates in combination with verapamil has been associated with reports of myopathy/rhabdomyolysis.; In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including trandolapril, may result in deterioration of renal function, including possible acute renal failure. ; No clinically significant pharmacokinetic interaction has been found between trandolapril (or its metabolites) and furosemide.; Co-administration of multiple doses of 10 mg of verapamil with 80 mg simvastatin resulted in exposure to simvastatin 2.5-fold that following simvastatin alone. ; If concomitant use of such agents is indicated, they should be used with caution and with appropriate monitoring of serum potassium (see PRECAUTIONS ).; Limit the dose of simvastatin in patients on verapamil to 10 mg daily. ; Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as verapamil may increase the plasma concentration of these drugs.; Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ; 
Verapamil$Drug$DB00661$SIROLIMUS$Drug$DB00877$true$Increase_Interaction$Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.; There have been reports that verapamil may elevate the concentrations of the oral anti-diabetic glyburide.; Verapamil therapy may inhibit the clearance and increase the plasma levels of theophylline.; Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; Concentrations of verapamil may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or St John s Wort.; Concentrations of doxorubicin may be increased by the administration of verapamil.; Verapamil therapy may increase serum levels of cyclosporin, sirolimus and tacrolimus.; When verapamil and colchicine are administered together, the potential inhibition of P-gp and/or CYP3A by verapamil may lead to increased exposure to colchicine (see PRECAUTIONS - Drug Interactions ).; 
Verapamil$Drug$DB00661$TACROLIMUS$Drug$DB00864$true$Increase_Interaction$Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.; Verapamil therapy may inhibit the clearance and increase the plasma levels of theophylline.; Concentrations of verapamil may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or St John s Wort.; There have been reports that verapamil may elevate the concentrations of the oral anti-diabetic glyburide.; Concentrations of doxorubicin may be increased by the administration of verapamil.; Verapamil therapy may increase serum levels of cyclosporin, sirolimus and tacrolimus.; When verapamil and colchicine are administered together, the potential inhibition of P-gp and/or CYP3A by verapamil may lead to increased exposure to colchicine (see PRECAUTIONS - Drug Interactions ).; 
Verapamil$Drug$DB00661$THEOPHYLLINE$Drug$DB00277$true$Increase_Interaction$Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). ; Concentrations of doxorubicin may be increased by the administration of verapamil.; Verapamil may inhibit the clearance and increase the plasma levels of theophylline.; When used concomitantly, inhalation anesthetics and calcium channel blocking agents, such as verapamil, should each be titrated carefully to avoid excessive cardiovascular depression.; Phenobarbital therapy may increase verapamil clearance.; There have been reports that verapamil may elevate the concentrations of the oral anti-diabetic glyburide.; When verapamil and colchicine are administered together, the potential inhibition of P-gp and/or CYP3A by verapamil may lead to increased exposure to colchicine (see PRECAUTIONS - Drug Interactions ).; Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ; Therapy with rifampin may markedly reduce oral verapamil bioavailability.; Verapamil therapy may inhibit the clearance and increase the plasma levels of theophylline.; Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.; When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, should each be titrated carefully to avoid excessive cardiovascular depression.; When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.; Concentrations of verapamil may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or St John s Wort.; It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.; Verapamil therapy may increase serum levels of cyclosporin, sirolimus and tacrolimus.; Verapamil therapy may increase serum levels of cyclosporin.; Verapamil therapy may increase serum levels of cyclosporine.; 
Verapamil$Drug$DB00661$Vecuronium$Drug$DB01339$true$Increase_Interaction$It has been reported that verapamil decreases neuromuscular transmission in patients with Duchenne's muscular dystrophy, prolongs recovery from the neuromuscular blocking agent vecuronium, and causes a worsening of myasthenia gravis. ; TARKA (trandolapril/verapamil hydrochloride ER) combines a slow release formulation of a calcium channel blocker, verapamil hydrochloride, and an immediate release formulation of an angiotensin converting enzyme inhibitor, trandolapril.; 
VRX496$Drug$DB05251$ATORVASTATIN$Drug$DB01076$true$Caution_Interaction$
